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 ABSTRACT 
SPECTRAL CHARACTERIZATION OF CYTOCHROMES CYP11A1 (aka P450scc) 
ACTIVE SITE AND CATALYTIC INTERMEDIATES  
Qianhong Zhu, B.Sc., M.S. 
Marquette University, 2015 
The Cytochromes P450 are monooxygenases which use dioxygen and 
endogenous reducing equivalents to generate highly reactive intermediates capable of 
performing several types of oxidative transformations, most commonly, hydroxylations 
via the so-called Compound I species. There are two main kinds of mammalian P450s: 
those functioning in drug metabolism and those that facilitate steroid biosynthesis. 
Steroidogenic P450s participating in the biosynthesis of steroid hormones are involved in 
a number of different pathways. CYP11A1, one of the steroidogenic P450s also known as 
P450scc, is the enzyme that converts cholesterol to pregnenolone through side chain 
cleavage between carbon 20 and 22. The overall process is a three step reaction. The two 
intermediates, 22(R)-hydroxycholesterol and 20R,22R-dihydroxycholesterol, bind more 
tightly than either cholesterol or pregnenolone. One of the most interesting aspects of the 
enzymatic cycle is that, while the first two reactions involve substrate hydroxylations, 
presumably proceeding through the Compound I species, the third reaction involves a 
side chain cleavage reaction that has been proposed to occur through Compound I attack 
on the diol fragment of the 20R,22R-dihydroxycholesterol.The present work employs 
resonance Raman (rR) spectroscopy to structurally characterize the enzyme active site 
structure. Also, in order to obtain a generally useful calibration procedure to permit 
reliable rR-based evaluation of the percentage of HS and LS population for CYP11A1 
and other P450s, a method was developed to relate HS/LS populations to measured 
intensities of spin state markers based on well-behaved CYP101 reference samples. 
These cross section values from P450cam high spin and low spin are used to determine 
the spin population in CYP11A1 complex with three different substrates and evaluate the 
effect of Adx binding. The work also clarifies certain confusing issues that had arisen 
from previously published spectroscopic studies of ferric and ferrous-CO states. Most 
significantly, the present work provides the first rR spectroscopic characterization of the 
oxy adducts for the three substrate-bound forms, providing some insight into the active 
intermediates involved in the three sequential reactions. 
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1 General Introduction 
1.1 Heme proteins 
Proteins are metalloproteins which contain an iron protoporphyrin IX (structure 
showed in Figure 1.1.1) as a cofactor. These types of proteins play very important roles in 
mammalian life. They can serve as oxygen transporter and storage1,  as a catalyst in a 
difficult reaction2, as electron transporter3 or for NO synthesis4. There are four main 
classes of heme proteins. 1) Globins serve as oxygen transporter and storage. 
Hemoglobin (Hb) in blood cells serves as oxygen transporter from high oxygen 
concentration in lung tissue to low oxygen concentration in bodily tissues. Myoglobin 
(Mb) in muscle can store oxygen until the cells need it.1 2) Electron transport proteins 
include cytochrome b5 and other cytochromes.
3 3) Nitrophorins serve as NO carrying 
protein.5,6 4) The last type, classified as oxidoreductases, is used as catalyst which can 
use O2 or H2O2 to oxidize the substrates, for example P450s, peroxidases, etc.
4  
 
Figure  1.1.1 Structure of iron protoporphyrin IX 
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1.1.1 Globins 
There are two main globins: hemoglobin (Hb) and myoglobin (Mb).1 Myoglobin 
is found in the muscle tissue which stores oxygen until the cells use it. Myoglobin is a 
monomer, a relatively small molecular weight (~16 kDa), which contains only one heme 
in one isolated polypeptide.7 The oxygen binds to the heme group, which serves as the 
sixth ligand, the trans-axial (so-called proximal) ligand of the myoglobin being an 
imidazole fragment of a histidyl residue. Comparing hemoglobin and myoglobin, 
hemoglobin is a tetramer which consists of four myoglobin-like subunits, two of them 
called α subunits and another two called β subunits, each of them containing a heme 
group.7 The ribbon diagrams of myoglobin and hemoglobin are shown in Figure 1.1.2.   
  
Figure 1.1.2 Ribbon diagram of myoglobin (left) and hemoglobin (right) with its α and β 
subunits represented in red and blue. 7 
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 With the conformational difference between Mb and Hb, their ability to bind 
oxygen is quite different. Myoglobin binds with oxygen according to a hyperbolic curve 
typical of at a simple bi-molecular chemical equilibrium. On the other hand, the curve for 
oxygen binding to Hb exhibits a sigmoidal (so-called “S-shaped”) curve that is 
characteristic of allosteric ligand binding, where early oxygen binding steps induce a 
global conformational change that enhances the affinity of remaining empty heme sites. 
This behavior is depicted in Figure 1.1.3, which shows the oxygen binding curves for Mb 
and Hb.8  As can be seen, at low oxygen pressure characteristic of bodily tissues, the 
binding affinity of Hb for oxygen is lower than that of Mb while at high oxygen pressure, 
as exists in the lung, the binding affinity of Hb and Mb are comparable. This process 
allows hemoglobin to more efficiently carry oxygen from the lung to the cell tissue.  
 
 
Figure 1.1.3 The oxygen binding curve by myoglobin and hemoglobin8  
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Though this description of the functional properties of hemoglobin allosteric 
binding is commonly accepted, the precise molecular transformations that give rise to this 
allostery are still not fully understood and are the subject of continuing interest. In fact, 
recently our group has been collaborating with that of Professor Spiro’s group at the 
University of Washington and I have succeeded in preparing judiciously designed hybrid 
hemoglobins to facilitate these studies, the results for a hybrid containing mesoheme and 
protoheme (i.e., [αmesoβproto]2 and [αprotoβmeso]2) having been recently published in the 
Journal of the American Chemical Society,9 with ongoing similar studies of the Fe/Co 
hybrids expected to conclude in the near future   Though not included in this dissertation, 
which is devoted to studies of Cytochromes P450, the experimental details involved in 
preparing these hybrids are included in Appendices section of this dissertation. 
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1.1.2 Cytochromes 
Heme proteins which serve as electron transfer proteins belong to a large family 
of cytochromes that are responsible to produce ATP. The cytochromes are classified to 
four groups according to the binding mode with heme: a, b, c, d and f. 10  Among these 
four groups, Cytb containing proto heme and Cytc containg a proto heme which is 
covalently bound with protein are the most studied cytochromes.  
The Cytb can be found in the mitochondrion of eukaryotes and in aerobic 
prokaryotes. It is an integral membrane protein, also known as bc1 complex, which has 
two heme groups with around 400 amino acid residues.11 The molecular weight is about 
40 kDa. Cytc can be found in inner membrane of the mitochondria which is a small 
protein with 103-112 amino acid residues. The molecular weight is around 12 kDa.3  
The electron transfer process involves a heme oxidation state change between 
Fe(II) and Fe(III). Cytochromes are performing reduction (from Fe(III) to Fe(II)) and 
oxidation (from Fe(II) to Fe(III)) reactions during the electron transfer process.12 This 
reaction is involved in the process generating ATP, which is for intracellular energy 
transfer. 
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1.1.3 Nitrophorin  
 Nitrophorin (NP) is one type of NO-carrying heme protein which can be found in 
the saliva of the blood feeding insects, the kissing bug (Rhodnius prolixus) and the 
bedbug (Cimex lectularius).5,6 The adult Rhodnius prolixus contains at least four NPs 
which are designated to NP1-4,depending on their relative abundance in the glands which 
have been widely studied.6 The NPs in the kissing bug bind with histamine and NO when 
NO releases, the histamine will be scavenged by coordination to the heme Fe while the 
NPs in bed bugs bind with two NOs, one to the heme and the another one to the cysteine 
which serves as the ligand when NO is absent. This requires the bond cleavage between 
the Fe and S from the cysteine group.  
Under physiological conditions, the neurotransmitter, NO, is oxidatively 
generated from arginine by nitric oxide synthase (NOS), with the soluble guanylate 
cyclase (sGC) acting as the NO receptor. NPs serve as a group of NO-carrying protein 
which enter the salivary gland then cause the diffusion of the NO with NOS then NO 
molecular binds with the NP instead. The low pH (5-6) 13 environment in the saliva helps 
stabilize the NP-NO complex with Fe(III) which makes this diffusion and binding with 
NP more favorable. NPs are insect protein and they will interact with the blood 
environment when they are sucking blood. The pH environment will change in blood at 
~7.4 versus the saliva 5-6.13 This drastic pH change causes some conformational change 
in some NPs which lead to the diffusion of NO from NPs. Then the NO receptor (sGC) 
binds with NO. 5,6 The NP is used for transport the NO molecular.  
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1.1.4 Heme oxidoreductases 
Heme-containing oxidoreductases are the main proteins studied in our lab. They 
can catalyze a wide range of reactions; for example, hydroxylation, bond cleavage, 
aromatization, etc.2 The reactions of interest in our lab are catalyzed through oxidation 
reaction on the substrates using O2 or H2O2. There are many types of enzymes which are 
capable of catalyzing oxidation reactions; for example, peroxidases, NOS, heme 
dioxygenases, heme-thiolate haloperoxidases and P450s.4 Since P450s will be discussed 
in next sections in a very detailed way, in this section basic summaries of some other 
oxidative heme enzymes are presented.  
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1.1.4.1 Peroxidases 
 
Due to the easy preparation of horseradish peroxidase (HRP), this type of enzyme 
became the first studied heme enzyme since 1903.14 The molecular weight of a 
peroxidase is 30-150 kDa15 with a histidine residue attached to the heme Fe through Fe-N 
bond. The ribbon diagram of HRP is shown in Figure 1.1.4.  
 
Figure 1.1.4  The ribbon diagram of horseradish peroxidase (HRP) 14 
 
Peroxidases can catalyze a wide range of reactions under the presence of peroxide 
such as oxidize the polymerisation of phenols and aromatic amines. The peroxidase 
reaction will go through a cycle similar with P450s.4,15 The first step of the cycle is that 
the peroxide, H2O2, removes one electron from Fe (III) and a second electron from 
porphyrin to generate an unstable intermediate called compound I which is a ferryl heme 
π cation radical, where one electron has been removed from the heme porphyrin 
9 
 
 
 
framework and another from the ferric iron to generate an oxo-Fe(IV) fragment, the 
peroxide being reduced to H2O.  In the second step, the electron donor substrate donates 
an electron to compound I which becomes compound II, a ferryl heme moiety, where the 
porphyrin radical has been reduced. In the last step, compound II is further reduced by a 
second substrate, regenerating the Fe(III) state. This process will produce another free 
radical and a molecular of H2O.  The substrates for HRP like peroxidase are usually 
phenols and aromatic amines. The scheme of this process is shown in Figure 1.1.5. 
  
1. Fe3+R + H2O2             Fe4+=O R·+ + H2O 
Compound I 
2. Fe4+=O R·+ + SH            Fe4+=O R + S· 
Compound II 
3. Fe4+=O R + SH             Fe3+ R + S· + H2O 
Figure 1.1.5 Catalytic cycle scheme of peroxidase (S: substrate) 4 
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1.1.4.2 Nitric oxide synthase (NOS) 
 
Nitric oxide synthase (NOS) catalyzes the synthesis of NO from arginine through 
two consecutive cycles.4,16 This type of enzyme can be found in many species, like 
mammals, fish, birds, invertebrates, and plants, bacteria.17 The most well studied NOSs 
are from mammals. There are three main types of NOS isozymes according to the gene 
sequence: neuronal NOS (nNOS) found in neuronal tissues in nervous system, inducible 
NOS (iNOS) found in macrophages in immune system, endothelial NOS (eNOS) found 
in endothelial cells in cardiovascular system.18  
The NOS has a cysteine in the proximal side and hydroxylates substrates through 
a general P450 like cycle.4,18 In the resting state, NOS bound with BH4, the heme is 
primary five coordinate with small component in six coordinate. Upon binding of the 
substrate, L-arginine (Arg), or N
ω-L-hydroxyarginine (NOHA), the heme becomes fully 
five coordinate. The general mechanism is shown in Figure 1.1.6. In the first step, the 
BH4 bound NOS in the resting state (I) is reduced by one electron from NADPH. The 
second step, this ferrous species binds with an oxygen molecule which forms ferrous-oxy 
complex (III). The third step, this ferrous-oxy complex structurally rearranges to ferric 
superoxide complex (IV) which is more reasonable for electron density distribution. 
These three steps are exactly the same as P450s which you will see in the P450 
mechanism cycle part. The forth step, the superoxide complex accepts an electron and a 
proton from BH4 to generate hydroperoxy complex (V). The electron from BH4 will 
reduce complex (IV) to a cationic pterin radical which is eventually reduced by a 
reductase domain and regenerate BH4. This step is different in P450s, which accept 
11 
 
 
 
electron from NADPH again and proton is from the surrounding environment, H2O or 
amino acid residues. Then the hydroxyperoxy complex is quickly protonated to form a 
very reactive π cation radical species, compound I (VI) with releasing of a water 
molecule. This complex insert the oxygen molecule to substrate Arg to form NOHA then 
the complex is back to its resting state.  
Through the second cycle, the complex formation from I-V is the same as the first 
cycle. The hydroxyl complex (V) reacts with substrate NOHA, generated from the first 
cycle, to generate NO and L-citrulline. The NO and L-citrulline then depart the active site 
for next physiological process in other place.  
 
Figure 1.1.6 The mechanism of NOS reaction cycle18 
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1.1.4.3 Heme oxygenase 
 
Heme oxygenase (HO) is one type of heme protein which catalyzes the heme 
degradation in order to release non-toxic heme fragments.4,19 Hemoglobin is the main 
source of heme. The heme groups from about 6-8 g of hemoglobin (molecular weight 64 
kDa) are degraded daily; i. e.,  degradation of 300 mg (molecular weight 656 g/mol) of 
protoheme.4 There are many types of HOs found in human, rat and bacteria. Human HO-
1 was is the first structure reported. The heme in HO is sandwiched between the proximal 
and distal helices, as shown in Figure 1.1.7, with a histidine group on the proximal side.  
 
Figure 1.1.7 The ribbon diagram of heme oxygenase20 
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The heme oxygenase system consist a heme oxygenase and a NADPH contained 
P450 reductase. The mechanism involves three cycles to generate biliverdin.4 The first 
step of the overall reaction is to form α-meso-hydroxyheme. The ferric heme Fe(III) is 
reduced to Fe(II) by one electron donated from NADPH contained P450 reductase. Then 
it binds with oxygen molecular to form oxy complex, most reasonably formulated as 
ferric superoxide Fe(III)-O-O-1. This complex accepts another electron from the reductase 
and a proton from a water molecule in the active site to form ferric hydroperoxide species 
Fe(III)-O-OH. Then the terminal oxygen reacts with the α-meso-carbon of the porphyrin 
to generate the ferric a-meso-hydroxyheme. Figure 1.1.8 shows the detailed mechanism 
of heme degradation. 
The second step is the verdoheme generation. The α-meso-hydroxyheme can be 
depronated to generate an Fe(II) radical with two resonance structures. This complex can 
go through two pathways to generate verdoheme. In the first pathway, the Fe(II) radical 
species can first accept an electron and then with bind with molecular oxygen and react, 
releasing CO to form verdoheme. The other pathways is that the Fe(II) radical species 
first binds with oxygen and reacts, releasing CO, and then is reduced by one electron to 
generate verdoheme. Even though the pathways are different, the two steps of binding 
with oxygen and being reduced by one electron are the same in the two pathways, as can 
be seen in Figure 1.1.8.  
The mechanism of last step, verdoheme to biliverdin, is not well understood. The 
proposed mechanism shown in Figure 1.1.8 is according to intermediates seen from the 
QM/MM calculation and crystallography studies.21,22 After generation, the reaction cycle 
is done then the biliverdin will be released from the active site of the protein.  
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Figure 1.1.8 Mechanism of heme degradation4 
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1.1.4.4 Heme-thiolate haloperoxidases 
 
Heme-thiolate haloperoxidases are among the most versatile biocatalysts in the 
heme protein family.4,23 Among all these types of enzymes, the most well-known one is 
chloroperoxidase (CPO), which belongs to haloroperoxidase family, which can oxidize 
chloride (Cl−), bromide (Br−) and/or iodide (I−), but not fluoride (F−). Figure 1.1.9 shows 
some of the halogenations catalyzed by CPO.23 As can be seen, CPO can catalyze 
oxidation of not only Cl, but also other halogens.   
 
Figure 1.1.9  Halogenation catalyzed by CPO 23 
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Besides halogenation, CPO can catalyze many types of reactions, for example, 
olefin oxidation, oxygenation insertion, sulfoxidation, etc.23 The Figure 1.1.10 shows all 
the reactions can be catalyzed by CPO.  
 
Figure 1.1.10 non-halogenation reactions catalyzed by CPO 23 
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Since CPO can catalyze a wide range of reactions, it becomes a very flexible 
catalyst compared with other heme enzymes. The proposed mechanism of the oxidation 
cycle23 is shown in Figure 1.1.11. In the first step the resting state (1), Fe(III) bound with 
S from cysteine on the proximal side, binds H2O2, then goes through a bond cleavage of 
O-O and release a H2O molecule to generate the reactive π cation radical species, 
compound I (2). This process needs two electrons transferred from the heme. Compound 
I is a very reactive species which can react with various types of substrates.     
 
Figure 1.1.11 Catalytic cycle of haloroperoxidase 23 
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1.2 Cytochrome P450s 
1.2.1 Discovery of P450s 
In 1955 Axelrod24 and Brodie25 first discovered that the oxygenase enzyme 
system in the endoplasmic reticulum of the liver. In 1958, Garfinkel26 and Klingenberg27 
reported the special CO bound pigment in the liver microsomes which showed a strong 
Soret absorption maximum at 450nm in the UV absorption spectrum (Figure 1.2.1). This 
special type of enzyme was named Cytochrome P450 according to its characteristic 
absorption feature.   
 
Figure 1.2.1 Absorption spectrum of Cytochrome P450-CO complex showing the 
characteristic Soret peak at ~ 450 nm 26,27 
 
 
19 
 
 
 
The electron spin resonance spectroscopy identified that protein is a low spin 
ferric form hemoprotein.28 In 1964, this liver microsomes pigment was purified and the 
properties were tested which proved the heme group was bound with a thiolate residue 
through S atom.29–32 This gives the reason that the strong absorption feature came from 
the charge transfer of Fe-S bound.33 Resonance Raman spectroscopy also provided 
definitive evidence that S was the cysteine residue which was covalently bond with the 
Fe in the heme group.33–35 
Because P450s can hydroxylate very different kinds of compounds and give 
specific stereochemistry configuration by using atmospheric oxygen,36 research on P450s 
covers a broad spectrum of scientific interests (Figure 1.2.2).37 
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Figure 1.2.2 P450 research fields and its application 37 
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1.2.2 Nomenclature 
There was no problem when there were only few P450 crystal structures. Name 
was given by its substrate, for example, P450cam (also known as CYP101), or its 
function, P450scc (also called CYP11A1), etc. However, as more and more P450 
enzymes have been discovered and characterized, it became apparent that the number of 
P450 genes and proteins is very large so it became necessary to develop a nomenclature 
system. The systematic naming took place since 1989 according to the gene evolution.38 
The nomenclature system uses symbol CYP as an abbreviation for Cytochrome. An 
alphanumerical code is used for P450 families, subfamilies and individual proteins.37 
Example is given below: 
 
Figure 1.2.3  Systematic nomenclature for P450s, examples given as CYP11A1 
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1.2.3 Catalytic cycle 
P450s can catalyze impressive range of reaction, such as ring expansion and 
carbon-carbon bond cleavage.36 In order to better understand the impressively diverse 
chemical reactivity accessible to these enzymes, we need to better understand what 
exactly is happening at the active site; i.e., what types of species are encountered in the 
catalytic cycles of these enzymes. The enzymatic cycle shows the process and 
intermediates generated during one cycle (Figure 1.2.4). Some enzymes can do multiple 
cycles and then release the product, for example CYP11A1 which converts cholesterol to 
pregnenolone through three consequential cycles.39,40 
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Figure 1.2.4 Catalytic cycle for general P450s 
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The cycle takes place from the resting state which is substrate free form. The 
heme iron in this state is a low spin (LS) ferric form and its sixth ligand is a water 
molecule from the water cluster in the distal pocket. The binding of a suitable substrate, 
such as camphor in case of CYP101, causes disruption of the distal pocket network of 
water molecules and displacement of the ligated water to generate a 5-coordinated heme 
with consequent stabilization in the high spin (HS) state.  
Now, the reduction potential of the HS heme increase which leads to facilitate 
electron transfer from the natural (or artificial) reductase to the substrate bound P450 
through redox partner, with the resultant ferrous state remaining in high spin (HS).34,41,42 
This relatively electron rich Fe(II) in its high spin (HS) state combines with the electron 
deficient dioxygen molecule.43 Based on a wealth of supportive spectroscopic evidence, 
this Fe(II)-O2 complex is most reasonably formulated as a ferric-superoxide species, 
Fe(III)-O-O-.42,44  
A second electron is transferred from a reductase also via electron transport 
system, the redox partner. Then it generates a negatively charged ferric peroxo group 
which is Fe(III)-O-O2-. This species can be quickly protonated by local transferred 
hydrogen from water or surrounding amino acid side chain. Then it becomes ferric 
hydroperoxo Fe(III)-(O-OH-). This complex can be further protonated, by a local donor, 
at the distal oxygen atom, promoting O-O bond cleavage, generating a highly reactive 
species, commonly called P450 Compound I. This species is best formulated as an Fe(IV) 
oxo species with the second oxidizing equivalent generating a heme based π-cation 
radical localized over the porphyrin macrocycle.2,42 Compound I is very reactive, but has 
been generated by artificial means and characterized in 2010.45 
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This extremely potent oxidizing species reacts with substrate to regenerate a ferric 
heme which, upon release of product and reorganization of the active site water 
molecules, returns to the ferric low spin (LS) resting state. This cycle can be interrupted 
by different conditions, and then end up at ferric substrate bound or ferrous form as 
shown in Figure 1.2.4.  
Spin state equilibrium: It is generally known that the binding of substrate will 
convert the enzyme to high spin, but there are many cases that only partially convert to 
HS, for example, CYP11A1 with substrate cholesterol showing partial HS and LS. DFT 
calculation discovered that there is very small difference between the energy of water-
bound resting heme state and that of methytriazolate-bound CYP121.46 This leads to the 
conclusion that the existence of two equilibrium binding modes between the water ligand 
and substrate is possible.46 Also the study of CYP121 binding with the antifungal drug, 
fluconazole (FLU), shows that an additional H-bonding interaction in the active site 
residues leads to low spin binding mode.47 Another important type of substrate are 
inhibitors. A so-called “Type 2” substrate/inhibitor provides a donor group that allows 
the substrate or inhibitor to coordinate to the heme iron, through Fe-N bond; for example, 
1-alkoxy-4-nitrobenzenes and 1,4-phenylenesiisocyanide bound to CYP1A1, which is 
six-coordinated complex.48 This shows low spin.  
One of the very effective techniques to study those intermediates is resonance 
Raman spectroscopy. 
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1.3 Resonance Raman 
Raman Spectroscopy technique was discovered by an Indian scientist C.V. Raman 
in 1928.49 It is used to study vibrational modes, rotational modes or other low-frequency 
modes in a system. It is done by scattering light from an intense source, in modern times 
a laser. Almost all of the photons are scattered with no change in energy; this is called 
Rayleigh scattering.49 However, some of photons will interact with the sample and be 
scattered at longer wavelengths, losing some energy to the sample, with the acquired 
energy generating a vibrationally excited state of the molecule (Raman scattering); i.e., 
analysis of the scattered light will reveal weak side bands whose frequency difference 
from that of the incident laser corresponds to the energy associated with a vibrational 
transition. Thus, the data one obtains is a spectrum directly analogous to what one obtains 
from an IR spectrum. If an incident photon encounters a molecule that is already in an 
excited vibrational level, it can gain energy form the molecule and be scattered as a 
higher energy photon; this is called ”anti-Stokes Raman scattering”. According to the 
Boltzman distribution, the excited vibrational states are not well populated at room temp 
and this population diminishes as the energy of the vibration increases. So, generally, 
observations are made on the so-called Stokes Raman bands. All of the scattered light 
will be focused by a collection lens and focused onto the entrance slits of a 
monochromator; the single monochromator used in our lab is equipped with a CCD 
detector. The setup is shown in Figure 1.3.1. 
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Figure 1.3.1 Raman scattering spectroscopy 
 
Because Raman scattering is a very weak process with low probability of photon 
and molecule energy exchange, to obtain good quality spectra, it is required to have a 
concentrated sample; e.g., 1Molar. This is the major problem with this method of 
ordinary Raman spectroscopy, low sensitivity. However, if a given sample possesses a 
strong electronic absorption band, using a laser line in resonance with that electronic 
absorption band can lead to great enhancements of the vibrational modes of the 
chromophoric molecule, an effect forming the basis for “resonance Raman spectroscopy”, 
which is now widely used and is the main techniques being used in this work.  
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A great illustration of resonance Raman spectroscopy is shown in Figure 1.3.2. 
Compare tris-phenanthroline Fe(II) complex of divalent ion with sulfate ion as a non-
enhanced internal standard. The complex has an intense (ε~104 M-1 cm-1) MLCT 
transition which shows the absorption band around 510 nm. With 647.1nm excitation, far 
from the MLCT maximum, the Raman spectrum is dominated by sulfate ion, SO4
2-, with 
ν(S-O) at 981cm-1. From inspection of the other three spectra, when the excitation lines 
approach the MLCT maximum, the characteristic modes of the coordinated ligand are 
strongly enhanced, dominating the spectrum even though the concentration of the 
complex is 1000 times less than that of the sulfate.50 
 
Figure 1.3.2 (A) structure of tris-phenanthroline Fe(II); (B) Absorption spectroscopy of 
tris-phenanthroline Fe(II); (C) Resonance Raman spectroscopy with different excitation 
laser lines 
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This great enhancement permits selective interrogation of chromophoric groups 
buried within complex molecular and biological matricies. For example, hemoglobin has 
four heme groups buried deeply in the protein with molecular weight at 64 KDa.51 The 
electronic absorption spectrum of human hemoglobin and the structure of heme group are 
shown in Figure 1.3.3. When the laser line is between 220 nm - 280 nm, the vibrational 
modes from four aromatic amino acids, Tyrosine, Phenylalanine, Tryptophan, and 
Histidine, can be observed because only these four amino acids have electronic 
absorption bands in this region.44 On the other hand, if the excitation line is near the 
strong Soret (ε~105 M-1cm-1) or Q (ε~104 M-1cm-1) π-π* bands of the heme, then the 
modes from the heme group will be selectively enhanced, in other words, we will be able 
to observe the modes associated only with the active site heme group.44,52 
 
Figure 1.3.3 Electronic absorption spectroscopy of human being hemoglo  bin and the 
structure of heme group 
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Now we can apply the resonance Raman spectroscopy to the study of Cytochrome 
P450s. Champion and his coworkers trapped the oxy form intermediate of CYP101 by 
using resonance Raman with 16O2 and 
18O2 isotope label. The bending mode, δ( Fe-O-O), 
was published in 1999.53 By subtracting, the two stretch modes ν(O-O) and ν(Fe-O) can 
be clearly seen.42,53,54 Figure 1.3.4 shows the spectrum of oxy-CYP101 and its oxygen 
isotope labels measured by 356 nm and 413 nm excitation lines. As it shows that by 
subtracting, one can clearly observe the Raman shift arising from the oxygen isotope 
labeling. The relative intensity of ν(O-O) increases while ν(Fe-O) decreases as compared 
with ν4 when the excitation line changes from 356 nm to 413 nm. This application of 
isotope labeling helps us to see the weak modes, or the modes buried within the envelope 
of strong heme modes. 
31 
 
 
 
 
Figure 1.3.4 Resonance Raman Shift by isotopic labeling of O2 of oxy-CYP101 at 
excitations of 356 nm (a-c) and 413 nm (d-f) 53 
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In addition to studying the oxy intermediate by resonance Raman, it is also 
possible to trap other “oxy intermediates”; for example, the ferric peroxo, hydroperoxo, 
or even Compound II. People realized The oxy intermediate is the most stable 
intermediate compared with later intermediates,42 but after addition of an electron to form 
a ferric-peroxo species, in most situations, proton transfer from active site surroundings is 
very efficient, promoting rapid reaction, with the complex quickly returning to its resting 
state.  So, the cycle just quickly finishes after adding an electron to the oxy intermediate, 
with no intermediates being seen under physiological conditions. The only way to trap 
and interrogate these fleeting intermediates is to only allow the electron to transfer but 
restrict the proton transfer. The only effective method to accomplish this is a method 
called cryoradiation by gamma ray which was pioneered by Martyn Symons in 1980s.55 
The method has been elegantly refined and used extensively by Brian Hoffman, Stephen 
Sligar and coworkers.54,56 The procedure for doing this is summarized below and shown 
in Figure 1.3.5. 
Step 1: The heme protein is prepared in a buffer (H2O or D2O) containing 20-30% 
glycerol, which ultimately is the free electron source. Using a reducing agent, such as 
Na2S2O4, the heme is reduced from Fe(III) to Fe(II), then 
16O2 or 
18O2 is bubbled through 
the solution and quickly frozen in liquid N2 to make sure the sample does not auto-
oxidize. At this stage, oxy-hemeprotein has formed, as is then confirmed using resonance 
Raman spectroscopy with Soret excitation. 
Step 2: One electron can be added to this oxy-hemeprotein by irradiating the 
sample under 60Co gamma ray source which will generate electrons from glycerol 
environment. The source is available at Notre Dame Radiation Laboratory. At this stage, 
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ferric peroxoanion is formed via migration of electrons, which can migrate at 77K, while 
other species, including protons, are not so mobile. The resonance Raman spectrum of 
this trapped peroxo- species can be collected at this point. 
Step 3: The ferric hydroperoxo complex can be generated at this point by 
annealing at different temperatures/times and monitoring the rR spectrum for changes 
associated with formation of a hydroperoxo species. In the case of the simple CYP101 
system, this proton transfer step is so efficient, even at 77Km this it was not possible to 
trap the peroxo form. However, employing the D251N mutant, which has a restricted 
proton transfer, 54,57 after annealing at 145 K to get rid of the excess radicals generated by 
gamma ray irradiation, it was indeed possible to observe the rR spectrum of the peroxo 
form of this CYP101mutant.58 Subsequent annealing to 187 K allowed proton movement 
to the heme site yielded the rR spectrum of the hydroperoxo form.54 The precise 
annealing temperature is more easily determined by using EPR which can detect the 
change from peroxo to hydroperoxo much faster than resonance Raman, 10 minutes verse 
a few hours of measurements. At this stage, ferric hydroperoxo is formed and the rR 
spectrum can be acquired.  
Step 4: Ideally if annealing further, Compound I will be formed but this species is 
too reactive to be seen yet. 
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Figure 1.3.5 Process of cryoreduction and annealing to generate intermediates at different 
stage 
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A brief set up for RR spectroscopy is shown in Figure 1.3.6. That equipment will 
allow us to measure samples at 77K all the time. The container, where the sample will be 
kept, is filled with liquid N2, and people who measure the sample can refill the liquid N2 
easily when the liquid N2 is evaporated. Samples can be measured with different laser 
lines and different frequency by adjusting the monochromator spectrometer. Annealing 
process is done by placing the sample in desired temperature cold bath and incubating for 
a certain time. The efficiency of annealing is confirmed by resonance Raman. 
 
Figure 1.3.6 Cryogenic resonance Raman measurements instrumental setup 
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According to the CYP101 absorption spectra, which are shown in Figure 1.3.7, it 
is known that the oxy-CYP101 has peak at 415 nm while hydroperoxo-CYP101 and 
peroxo-CYP101 both have an absorption feature at around 440 nm.54  
 
Figure 1.3.7 Absorption Spectra of CYP101 before and after cryoreduction54  
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From the absorption spectrum for CYP101, the Soret is at 415 nm for oxy sample 
and 440 nm for peroxo and hydroperoxo samples. The excitation line 442 nm from 
He:Cd laser was used to measure peroxo and hydroperoxo complexes which were 
generated after cryo-irradiation and annealing. After gamma irradiation, resonance 
Raman spectrum is shown in Figure 1.3.8. From the difference spectrum done by 
subtracting, it clearly shows H/D shift which means the sample is sensitive to H2O or 
D2O. From the peroxo-CYP101 structure, this complex should not be sensitive to H or D 
buffer because the proton has not transferred to the complex yet. The only reason for this 
to happen is that the proton is already transferred to the peroxo-CYP101 complex so the 
intermediate trapped here is the hydroperoxo-CYP101. The proton shuttle for this 
enzyme system is so efficient. It delivers electron even at 77 K.59 
 
Figure 1.3.8 Resonance Raman spectra of CYP101 after gamma irradiation by using 442 
nm excitation line. 
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Better method needs to be introduced to restrict or slow down the proton transfer. 
In 2008, Denisov et al discovered that asparatic acid 251 and threonine 252 are fragments 
in a so-called proton shuttle, which transfers proton to the oxy forms. Mutation from 
aspartic acid 251 to asparagine (D251N) will break or slow down the proton transferring 
process.60 Figure 1.3.9 shows the proton shuttle and the active site with absorption 
spectroscopy. From the absorption spectroscopy, peroxo-CYP101 and hydroperoxo-
CYP101 are showing differently. That means peroxo-CYP101 can be observed after 
gamma irradiation at 77K which process only allows an electron to move and with the 
slow down proton transfer shuttle done by mutation from aspartic acid 251 to asparagine 
restricts the proton transfer to the complex. With further annealing at 185K, one proton 
transfers to the complex so the hydroperoxo-CYP101 is formed and observed.54,60 
Resonance Raman has been used to characterize the trapped peroxo and hydroperoxo 
intermediates. 
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Figure 1.3.9 Mutation with proton shuttle view in the active site and its absorption 
spectroscopy 
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The Figure 1.3.10 shows the resonance Raman spectroscopy taken at 4C and 
77K for the oxy-CYP101 mutant. Comparing the spectra taken at two different 
temperatures, the shift at 1134 cm-1 has two modes shown at 77K spectra but not 
observed at 4C. This observation impressively shows that there are two oxy modes in 
the active site, one associated with hydrogen bonding, another one not, as they can be 
seen compared with the difference between D2O and H2O buffer. These two modes are 
because of the presence of an H-bond donor in the hem distal pocket, with the H-bonded 
form showing a lower ν(O-O) stretching mode, shifted by ~10 cm-1.58  
 
Figure 1.3.10 Resonance Raman spectroscopy at 4C and 77K with D2O and H2O buffer 
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The Figure 1.3.11 shows the spectrum after gamma irradiation and after annealing. After 
gamma irradiation, one electron transfers to the complex and peroxo-CYP101 is form. From the 
left spectrum in Figure 1.3.11, stretching mode of O-O bound does not have the H/D shift. After 
annealing to 185K, at this temperature allows the proton transfers to the complex and forms 
hydroperoxo-CYP101, so H/D shift is observed. 60 
 
 
Figure 1.3.11 Resonance Raman spectroscopy taken after gamma irradiation (left) but not 
annealing and after annealing at 185K (right) 
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Nano-disc technology61 has been introduced because there are some membrane 
bound enzymes, for example Cyt P450 2B4 and its reductase, Cyt b5 and its reductase 
(Figure 1.3.12). These membrane bound enzymes have hydrophobic tails which bound 
tightly with the membrane anchors so they are not soluble in aqueous, in other words, 
they will tend to aggregate after dissolving in aqueous solution through the hydrophobic 
tails.  
 
Figure 1.3.12 Membrane bound protein with hydrophobic tail bound with membrane 
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Nano-disc is made to avoid the aggregation. This technique was developed and  
employed by Stephen Sligar and coworkers.61,62 The nano-disc is made of phospholipid 
bilayers which are assembled by two membrane scaffold proteins. The schematic view of 
nano-disc is shown in Figure 1.3.13 left. The middle one is the membrane bound enzyme 
incorporated in nano-disc. If the reductase of one enzyme is membrane bound also then 
both enzyme and its reductase can incorporate within a single nano-disc as shown in the 
right. The redox partner of CYP11A1, Adx, binds with CYP11A1 through the proximal 
side so Adx is not membrane bounded.  
 
Figure 1.3.13 (left) nano-disc lipid bilayer with membrane scaffold proteins; (middle) 
mammalian P450s incorporated with nano-disc; (right) P450 and its reductase 
incorporated with nano-disc 
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The great advantage of this nano-disc technique can be very effectively 
demonstrated by resonance Raman spectroscopy. Results are shown in Figure 1.3.14. The 
top two spectra were taken with the samples in the conventional media, which are 50 mM 
phosphate buffer, 20 % glycerol, 0.1% Emulgen 913, 1 mM DTT. As can be seen, both 
samples contain a mixture of HS and LS species and there is almost no spin conversion 
upon addition of the substrate testosterone (TST). After making the enzyme incorporated 
with nano-disc, the substrate-free sample shows almost purely LS form, as expected, and 
upon adding a large amount of TST, there is a conversion to ~ 75% percent of high 
spin.63 Other effects may involved when using detergent, for example, detergent can 
denature the protein; glycerol can have some impact on the spin state conversion.64  
 
Figure 1.3.14 Spin population change after substrate bound in conventional media and 
nano-disc incorporated methods 
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1.4 Overview of my research 
The main goal of this research is to characterize the stable and unstable 
intermediates of CYP11A1. For stable species of CYP11A1 (i.e., ferric state and ferrous-
CO state) there are two high spin (HS) substrates and one low spin (LS) substrate. In 
order to evaluate the heme structural change and spin population change when CYP11A1 
binds with three natural substrates in the ferric state, we used CYP101 as a reference 
protein to obtain a generally useful calibration procedure to permit reliable rR-based 
evaluation of the percentage of HS and LS population for CYP11A1 complex with 
different substrates and with the redox partner Adx.  
CYP101 is an ideal reference because CYP101 gives 96% LS when it is substrate 
free and 95% HS when it binds with natural substrate camphor. In Section 2, a detailed 
description will be given of how this method was developed and tested to show its ability 
to evaluate HS/LS population ratios for several different P450s.  
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2 Using resonance Raman cross-section data to estimate the spin-state populations 
of cytochromes P450 
2.1 Introduction  
The cytochromes P450 (CYPs) are heme-based monooxygenases responsible for 
the oxidative metabolism of a huge number of relatively inert substrates, including 
pharmaceuticals and other xenobiotics, and for the biosynthesis of essential steroid 
products.2,42,65–67 Substrate binding initiates the enzymatic cycle by triggering a crucial 
low spin (LS) to high spin (HS) state change facilitating reduction to the ferrous heme 
intermediate that rapidly binds oxygen; subsequent transfer of an electron and two 
protons transfer generates the highly reactive π cation radical Compound I.68  The resting 
state gives a LS which is believed that Fe is six coordinated with H2O from a water 
cluster as ligand. Binding with substrate will kick off the water molecular and then Fe 
becomes five coordinated. In many cases, enzymes or proteins will not give a 100% of 
high spin or low spin when binding with substrate or not. Or situation will be that no spin 
state change during binding of substrate. One reason for that could be the aggregation of 
the protein which blocks the entrances for substrates entering the active site. Another 
reason will be the substrate serves as a sixth ligand of Fe. Other situation will be that 
binding of substrates does not show a full change which is more interesting to study what 
is exactly happened in the active site. No matter which situation, it is very important to 
know how much HS or LS of the protein or enzyme complex. 2,42,69,70 
Resonance Raman (rR) spectroscopy can effectively document the presence of HS 
or LS states of the ferric heme by appearance of distinctive frequencies observed at 
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~1485 cm-1 for high spin marker and 1500 cm-1 for low spin marker.44,71,72 Resonance 
Raman can also allow to check samples at different condition, for example, pH dependent 
samples, temperature dependent samples, ionic strength affected samples, etc. All these 
benefit people to check enzyme or protein at different stage by rR quickly. Given recent 
advances in producing and stabilizing these extremely important enzymes,60,61,73 it is 
anticipated that applications of rR to these proteins will now expand considerably. The 
purpose of this work is to provide a systematic approach to utilize rR spectroscopy to 
reliably estimate spin-state populations for different substrate/enzyme combinations. 
Cytochrome CYP101, an ideal reference protein, exhibits an almost complete spin-state 
conversion upon binding its natural substrate, camphor, switching from 96% LS to 95% 
HS.74  
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2.2 Methods and experiments 
2.2.1 Expression of CYP101 
The 10g LB Agar was mixed with 250 ml of deionized water in a plastic flask. 
The solution was then shaken to let the powder dissolve. The solution was microwaved 
untill small bubbles formed, and then shaken well. This process was repeated until the 
solution becomes clear. The solution was then placed in the hood and cooled down. 
When the solution was not hot, the antibiotic ampicillin was added to the solution to get 
final concentration of ampicillin at 100 µg/ml. About 20 ml of the solution was poured in 
the previous labeled Petri Dish. The Petri Dish was left in the hood for a while to let the 
solution become a solid gel. After the solution became solid gel, an autoclaved wooden 
stick was used to apply a small amount of CYP101 in BL21 E. coli cells which were 
purchased from Biolabs. The cell was spreaded using autoclaved glass beads. The cell 
was then incubated at 37 C for overnight to allow the cells to grow.  
Preparation of the 2YT culture media: 1 L of 2YT culture media was made with 
16 g of bacto tryptone, 10 g of bacto yeast and 5 g of NaCl, then adding water up to 1 L. 
The 2YT was placed in the plastic culture flask and then autoclaved. The 2YT media was 
cooled down and then the antibiotic ampicillin was added to a concentration of 100 µg/ml. 
A one percent solution of ampicillin contained 2YT media was placed in the small flask. 
A wooden stick was used to transfer one clone of the CYP101 cells from the Petri Dish to 
the small flask. The sample was incubated at 37 C in the shaker with shaking rate of 250 
rpm for overnight. 
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 The 2YT culture was warmed in the large container and culture containing 
ampilcillin, which had been growing over night in the small flask, was transferred back to 
the large container. The cultures were incubated at 37 C with a shaking rate of 250 rpm 
until an OD600 (the optical density of the culture at 600 nm) of 0.8-1.0 was reached. The 
bacterial growth was slowed down by reducing the speed of shaking to 190 rpm and the 
temperature was reduced to 24 C. The cells were induced to express CYP101 by 
addition of 1 mL of 1 M IPTG to 1 L 2YT media culture and δ-ALA (to a final 
concentration of 30 µM). The δ-ALA is the first precursor of heme biosynthesis. Solid 
FeCl3 was added to the container to reach a concentration of 80 mg/L.  
After 21 hrs of induction, 0.2 g/L of camphor was added to each of the large 
flasks to yield a final concentration of 1 mM followed by 2 hour incubation at room 
temperature with shaking at 190 rpm. The cells were harvested by centrifuging at 8,000 
rpm for 10 minutes. The wet cells were weighed and stored in a -80 C freezer. The yield 
of the cells was about 10 g/L media. 
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2.2.2 CYP101 purification 
The lysis buffer was made at a ratio of 1 g of wet cell with 3 mL of lysis buffer. 
The lysis buffer contained 50 mM Tris buffer pH=7.4, 25 mM KCl, 1 mM camphor, 1 
mM phenylmethylsulfonylfluoride (PMSF), 1 µM leupeptin, 1 µM antipain, 1 µM 
pepstatin, 32 units/mL DNase, 3 units/mL RNase and 1 mg/mL lysozyme. The wet cells 
were mixed with lysis buffer. The mixture was placed on the shaker with slowly shaking 
at 4 C for 30 minutes to allow the wet cells to fully disperse in the buffer. The mixture 
was transferred to a 50 mL plastic beaker for sonication. The cells were then sonicated 5 
times for 1 minute, each at a power of 6 and a 50% duty cycle. During the sonication 
process the cells were kept on ice and were allowed to cool for 5 minutes between cycles. 
After sonication, the sample was centrifuged for 10 minutes at 8,000 rpm 4 C to remove 
the cell debris, which stuck on the wall and the bottom of the centrifuge bottle. The 
supernatant was centrifuged for 2 hours at 20,000 rpm under 4 C. Crude CYP101 was 
obtained.  
The crude CYP101 was concentrated under high pressure of N2 with a 
concentrating device using the membrane transmited only molecules of MW <50,000. 
The buffer was exchanged with 50 mM Tris buffer pH=7.4, 25 mM KCl, 1 mM camphor; 
i.e., the appropriate running buffer for the subsequent chromatographic separation. The 
concentrated sample was applied to a DE53 column previous equilibrated with the above 
mentioned buffer. The column was eluted with the same buffer until there was no colored 
eluent. The CYP101 bound on the top of the column shown a brown band. The protein 
was then eluted by means of a linear salt gradient with 50 mM Tris buffer pH=7.4, 0-300 
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mM KCl, 1 mM Camphor until the all the brown band was eluted. The protein was 
collected as 2 mL fractions. The UV spectrum was checked and samples with Rz 
(A391/A280) > 0.5 were pooled together for further purification. 
The Rz > 0.5 fractions were concentrated to 500 µM. The of (NH4)2SO4 was 
added to CYP101 to reach the (NH4)2SO4 concentration to 75 mg/mL with slow addition 
and constant stirring to avoid precipitation. Then the entire sample was loaded to a 
phenyl sepharose hydrophobic column, which had been previously equilibrated with 50 
mM Tris buffer pH=7.4, 50 mM KCl, 1 mM camphor and 25% (NH4)2SO4 (143 g/L). 
The column was washed with the same buffer. The protein was then eluted by means of a 
linear salt gradient with 50 mM Tris buffer pH=7.4, 50 mM KCl, 25%-0% (NH4)2SO4, 1 
mM camphor. The protein was collected as fractions. The UV spectrum was checked and 
samples with Rz (A391/A280) > 1.0 were pooled together for further purification. 
The Rz > 1.0 fractions were concentrated to 500 µM. Then they were loaded on a 
P-100 Biogel column with 100 mM PB pH=7.4, 100 mM KCl, 1 mM camphor. CYP101 
was collected as 1 mL fractions. The UV spectrum was checked and samples with Rz 
(A391/A280) > 1.6 were pooled together. Pure CYP101 was obtained, concentrated to 500 
µM and stored in a -80 C freezer for future use. 
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2.2.3 Preparation of substrate free CYP101 
The substrate free form of CYP101 was prepared by passing pure CYP101 
through a Sephadex G25 column slowly with 50 mM MOPS (morpholino-propane 
sulfonic acid) adjusted pH to 7.4 by using 50 mM phosphate buffer to pH=7.4. The purity 
of substrate-free CYP101 was checked by UV spectroscopy. If there is any trace left of 
absorption at 391 nm, then the sample was passed through the G25 column again. The 
MOPS buffer was removed by passing the protein through a separate Sephadex G25 
column, which had been equilibrated with 100 mM PB pH=7.4, 100 mM KCl. The 
purified substrate free samples needed to be processed and analyzed at the same day in 
order to minimize the P420 formation during the experimental process.  
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2.2.4 Resonance Raman spectroscopy with CYP101 
Resonance Raman spectrum were obtained by using a Spex 1269 spectrometer 
equipped with Spec-10 LN-cooled detector (Princeton Instruments, NJ). The excitation 
line used to measure CYP101 with substrate and substrate free was 406.7nm from a Kr+ 
laser. Fenchone was used to calibrate the spectrum, which was processed by Grams/32 AI 
software (Galactic Industries, Salem, NH). Rayleigh scattering was removed with a 
Notch filter. The power used to measure both substrate free and substrate bound sample 
is 15 mW. The spectrum was obtained at room temperature with a slit of 150 µm. Each 
spectrum was scanned 30 times at high frequency and low frequency. The NMR tube 
containing sample was gently spun under house N2 gas which avoided the over-heating 
on the sample by continuous laser beam shining on the sample.  
The substrate free and substrate bound sample were prepared by pairs. The 
buffers were made in 100 mM PB pH=7.4, 100 mM KCl with 500 mM sulfate for 
CYP101 substrate free and CYP101 substrate bound. The buffer was separated into two 
parts, one was for CYP101 substrate free, and the other one was for the CYP101 
substrate bound. For the CYP101 substrate bound part, camphor was added to make the 
camphor concentration equal to 5 mM.   
Second, a CYP101 substrate free sample was made and distributed to 6 small 
vials, each vial containing 10 µL with protein concentration at 400 µM. So each vial had 
the same protein concentration. These 6 vials were grouped into two groups. Each group 
had 3 vials. The 120 µL of substrate free buffer was added to one group of vials to make 
the sulfate (SO4
2-) contained substrate free samples. The same amount of substrate bound 
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buffer was added to another group of vials to make the sulfate (SO4
2-) contained 
camphor-bound sample. By doing this, all the vials had the same concentration of 
CYP101 and sulfate ion.  
Total sample volume was 130 µL and the detailed sample information is 
summarized below: 
SF1, SF2, SF3: 10uL of ~400mM substrate free CYP101 in 100 mM PB pH=7.4, 100 
mM KCl buffer  + 120uL buffer of 100 mM PB pH=7.4, 100 mM KCl, 0.50Na2SO4; 
SB1, SB2, SB3: 10uL of ~400mM substrate free CYP101 in 100 mM PB pH=7.4, 100 
mM KCl buffer  + 120uL buffer of 100 mM PB pH=7.4, 100 mM KCl, 0.50Na2SO4, 5 
mM camphor. 
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2.3 Results and discussion 
2.3.1 Expression and purification of CYP101 
The expression and purification of CYP101 is described in Section 2.2. The UV-
Visible absorption spectra of the pure (Rz = 1.60) CYP101 and the reduced CO form of 
CYP101 are shown in Figure 2.3.1. Optical data of CYP101 has Soret band at 391 nm; 
the previously reported εmM =102.75 
 
Figure 2.3.1 UV-Vis absorption spectra of native CYP101 and its reduced CO form 
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The procedure to prepare CYP101 was described in Section 2.2.3. The overlap of 
UV-Visible absorption spectra of the pure (Rz = 1.60) CYP101 and its substrate free 
form are shown in Figure 2.3.2. Optical data of CYP101, substrate-free form, showed the 
Soret band at 417 nm, with εmM =119.76 The intensity of CYP101 substrate at 417 nm is 
higher than the intensity of CYP101 at 391 nm. 
 
Figure 2.3.2 UV-vis spectrum of overlap CYP101 substrate bound and CYP101 substrate 
free  
 
 
 
 
 
 
 
57 
 
 
 
2.3.2 Determination of Relative Resonance Raman Spin-State Marker 
Intensities for substrate-free and Camphor-bound CYP101 
As was described in earlier sections, efforts are being made to explore the 
possibility that resonance Raman spectroscopy might serve as a self-sufficient technique 
to determine spin-state populations for cytochromes P450, possibly as a generally useful 
method for a variety of P450s. The basic idea is to use an internal standard to determine 
accurate estimates of the relative intensities of the major marker bands for spin-state; i.e., 
the ν3 for the substrate-bound high spin (HS) state, occurring at ~1485 cm-1 and the ν3 for 
the substrate-free low-spin (LS) state, which appears near 1500 cm-1. The strategy is to 
employ a (non-resonance enhanced) internal standard, Na2SO4, in both solutions so as to 
give a standard band with fixed frequency and intensity. 
 
Figure 2.3.3 The resonance Raman spectra of ferric CYP101 substrate-free sample (A) 
and substrate-bound (B) sample. Spectra measured with 406.7nm excitation line and 
normalized to the sulfate band at 981 cm-1 
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The results, shown in Figure 2.3.3,  the spin-state change is observed as a shift of 
ν3 from 1502 cm-1 (LS) to 1488 cm-1 (HS). To estimate relative rR cross sections for the 
substrate-free (SF) and substrate-bound (SB) samples, three samples of these two forms, 
each containing 0.500M internal standard Na2SO4, were measured, and their spectra 
were analyzed using the following peak fitting procedure. The SO42- bands at 981cm-1 
(and all heme modes) were found to fit best with a 30% Gaussian/70% Lorentzian 
function. The average band width for the sulfate mode for all six spectra was 10.1 cm-1; 
the resulting band widths of the spin-marker bands were 11.5 cm-1 (1488 cm-1) and 11.3 
cm-1 (1502 cm-1). 
For the normalized the ν3, we can obtain 9 number ratios of YHS/YLS by 
comparing the area of ν3 in substrate bound with that in substrate free form. Noting that 
SF CYP101 is 96% LS, and the camphor-bound CYP101 is 95% HS,74 the operative 
relative intensity values, YLS and YHS, were derived by dividing the raw relative 
intensities by 0.96 and 0.95 factors, respectively. Results were listed in Table 2.3.1 for 
excitation line 406.7 nm and 413.1 nm. 
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Table 2.3.1 The calculated ratios of relative peak areas (YHS/YLS ) for a series of 
substrate-bound and substrate-free samples of CYP101. The spectra were measured with 
406.7 and 413.1 nm excitation lines 
406.7 nm 413.1 nm 
SB1/SF1 1.23 SB1/SF1 1.17 
SB1/SF2 1.13 SB1/SF2 1.15 
SB1/SF3 1.23 SB1/SF3 1.16 
SB2/SF1 1.28 SB2/SF1 1.19 
SB2/SF2 1.18 SB2/SF2 1.17 
SB2/SF3 1.29 SB2/SF3 1.18 
SB3/SF1 1.30 SB3/SF1 1.25 
SB3/SF2 1.20 SB3/SF2 1.23 
SB3/SF3 1.30 SB3/SF3 1.24 
average: 1.24 ± 0.06 average: 1.19 ± 0.04 
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The average is 1.24 for excitation line 406.7 nm and 1.19 for excitation line 413.1 
nm, indicating a slightly higher, but significant, difference in the ratios at the two 
excitation lines. Although of borderline significance, this smaller value of 1.19 is 
reasonable, because the 413.1 nm line is closer to resonance with the Soret band of the 
LS sample (417 nm). In order to expand the potential applications of this procedure, these 
ratios were also calculated for the ν4 and ν7 modes with both excitation lines listed in 
Table 2.3.2. These data can be used to normalize spectra in different regions. One can 
apply the YHS/YLS ratio of 0.21 ± 0.013 for the intense ν4 mode when normalizing high-
frequency spectra, and in the low frequency region, one could utilize the 0.38 ± 0.020 
ratio for ν7 mode.  
Table2.3.2. The calculated cross section ratios between substrate-bound and substrate-
free samples for the ν7, ν3 and ν4 modes, measured with 406.7 and 413.1 nm excitation 
lines 
 
          Mode 
YHS/YLS 
406.7 nm 413.1 nm 
ν7 0.38 ± 0.020 0.216 ± 0.003 
ν3 1.24 ± 0.06 1.19 ± 0.04 
ν4 0.21 ± 0.013 0.135 ± 0.005 
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Given that the electronic spectra of both the HS and LS states of the bacterial 
CYPs correspond well with those of mammalian CYPs, it is reasonable to expect that the 
value of 1.24 derived here for CYP101 should be valid for the spectra of mammalian 
CYPs. To evaluate this issue, the derived 1.24 value was applied to calculate the 
percentage of spin-state conversion upon substrate binding of several mammalian CYP 
available in our laboratory; i.e., CYP2B4, ND:CYP3A4, and ND:CYP17.77–79 The 
percentages of LS and HS states calculated from rR spectra (406.7nm excitation) using 
the method presented earlier were compared with the percentages independently derived 
by other workers from available UV–Visible data (Table 2.3.3).  
Table 2.3.3 The calculated percentage of spin-state populations in various cytochromes 
P450 measured with 406.7nm excitation line and using the YHS/YLS ratio of 1.24  ν3 
modes 
 
Protein 
Resonance Raman UV-Vis 
% High Spin % Low Spin % High Spin % Low Spin 
CYP2B4 
+ Butylated hydroxytoluene 
  
94 
 
6 
  
93a 
 
7 a 
CYP3A4 SF 5 95 1177 8977 
+ Testosterone 74 26 80-9277,78 877,78 
+ Bromocryptine 80 20 9377 777 
+ Erythromycin 19 81 22
77 7877 
CYP17 
    + Progesterone 94 6 97
 a 3 a 
+ 17-hydroxyprogesterone 59 41 62
 a 38 a 
Note: a was from personal communication 
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As can be seen, the data matched quite well for CYP2B4 with butylated 
hydroxytoluene, CYP3A4 both SF and with erythromycin, as well as CYP17 with 
progesterone, and 17-hydroxyprogesterone. The value obtained here for the testosterone-
bound ND:CYP3A4 falls within the range reported for the measurements with UV–
Visible spectrophotometry; as discussed more thoroughly in several earlier works dealing 
with substrate-binding equilibria and spin-state conversion for these systems,77–79 the 
percentage LS to HS conversion is not linearly related to the number of bound substrates 
and is further complicated by the fact that substrate access to enzyme also depends on 
partitioning of the substrate into the lipid bilayer of the nanodisc. Similar complications 
can also be encountered for the bromocryptine-bound samples of the ND:CYP3A4 
system and may account for the slightly larger, but not unreasonable, discrepancy seen 
here; i.e., 80% vs 93%.80 
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2.4 Summary 
The cross section ratio in this study is 1.24 for excitation line 406.7 nm and 1.19 
for excitation line 413.1 nm. One can use these two numbers to calculate the spin 
population through resonance Raman data of ferric data measured by 406.7 nm or 413.1 
nm lines. This method eases the way of determining the substrate binding, substrate 
exchange, redox partner binding, etc from the spin population change. The cross section 
ratio also helps to demine the change in different ionic strength buffer, pH dependence, 
etc. In section 3, I used this data to determine the spin population change of CYP11A1 
when binding with different substrates, Adx effect, and ionic strength effect.  
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3 Biophysical studies of CYP11A1, ferric, ferrous-CO and oxy-forms with effect of 
redox partner Adx 
3.1 Introduction  
3.1.1 Mammalian P450s 
Mammalian P450s are mainly membrane bound or incorporated P450s.2 P450s 
metabolize thousands of xenobiotics. According to the substrates that P450s metabolize, 
there are two main kinds of P450s: steroidogenic P450s and drug metabolism P450s.  
Drug metabolism P450s can metabolism about 75% of the drugs in the market.2,81 
Among those drug metabolism P450s, CYP3A4 metabolizes around 50%, both CYP2C19 
and CYP2D6 metabolize around 13% each. Figure 3.1.1 shows the main enzymes which 
metabolize the marketed drugs and main CYPs metabolizing marketed drugs.81 
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Figure 3.1.1 (left) main enzymes metabolize marketed drugs; (right) main CYPs 
metabolize marketed drugs 
 
Comparing the active sites of steroidogenic P450s and drug metabolism P450s, 
the size of the typical active site in drug metabolizing P450s is much larger than in the 
cases of the steroidogenic P450s. For example the size of active site in CYP3A4 is 1386 
Å3 while for CYP11A1 is only about 600 Å3.39,40,63  
A given drug metabolizing P450s can bind and process a wide range of 
structurally different substrates and some can bind up to several substrate molecules 
simultaneously, while steroidogenic P450s can only bind one substrate molecule at a time, 
with high specificity for the natural substrate. Drug metabolizing P450s typically perform 
multiple and relatively non-specific hydroxylations on a bound substrate, whereas 
steroidogenic P450s generally perform multiple highly regio- and stereo-specific 
hydroxylations or other oxidative transformations on the single natural substrate. For 
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example CYP11A1 converts cholesterol to pregnenolone through three-hydroxylation 
cycles.42 
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3.1.2 CYP11A1 (aka P450scc) 
Steroid hormones help control metabolism, inflammation, immune functions, salt 
and water balance, development of sexual characteristics, and the ability to withstand 
illness and injury. The steroid hormones are produced through multiple pathways which 
go through six different P450s: CYP11A1, CYP17, CYP21, CYP11B1, CYP11B2, and 
CYP19. Figure 3.1.2 shows the pathways and the function of each P450.2  
The steroid hormones synthesis starts from the conversion of cholesterol to 
pregnenolone which is catalyzed by CYP11A1. This is the first step and the rate 
determining step.2 The product, pregnenolone, is produced by the side cleavage between 
C20 and C22. The pregnenolone is the precursor of the following steps which are 
catalyzed by CYP17, CYP21, CYP11B1, CYP11B2, and CYP19.  
68 
 
 
 
Figure 3.1.2 Biosynthesis of steroid hormones82 
 
Steroidogenic cytochromes P450 play important roles in the synthesis of steroid 
hormones that are essential for maintenance of mammalian life.2,42 Ultimately, all of 
these crucial hormones are generated from a common parent hormone, pregnenolone. 
The pregnenolone is derived from cholesterol in a complex process mediated by the 
multifunctional steroidogenic P450, CYP11A1. The CYP11A1 is an inner mitochondrial 
protein of the adrenal cortex also known as cytochrome P450scc. The CYP11A1 catalysis 
the side cleavage process occurring between C20 and C22 of the cholesterol (Figure 
3.1.3).  CYP11A1 converts cholesterol to pregnenolone which triggers the first step of 
steroid synthesis.40 This is the rate limiting step in the steroid synthesis pathway.2 The 
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whole process is catalyzed by CYP11A1 through three sequential steps illustrated in 
Figure 3.1.3, where the first two steps convert cholesterol (CH) to 22R-hydrocholesterol 
(22R-OHCH) and then to 20R,22R-dihydroxycholesterol (20R,22R-DiOHCH), with the 
third stage leading to a bond cleavage between C20 and C22, thereby forming the key 
product, pregnenolone, and another small molecule, 4-methylpentanal (also called 
isocaproaldehyde).39,40 Accumulation of isocaproaldehyde will decrease the viability of 
Y1 cells,83 which are responsible for producing 20αdihydroxyprogesterone and 11β,20α-
dihydroxyprogesterone in the steroid synthetic process.84Aldose reductases (AR), 
cytosolic monomeric enzymes that belong to the aldo-keto reductase (AKR) superfamily, 
are able to reduce isocaproaldehyde.85 This superfamily can reduce  carbonyl groups 
from natural or synthetic substrates, including aliphatic and aromatic aldehydes, ketones, 
keto prostaglandins, ketosteroids and xenobiotics.85  It has been established that in mice 
Akr1b7 is the main isocaproaldehyde reductase and that Akr1b3 serves as a minor 
reductase for this side-product. 83,85–88  
The well established enzymatic cycle of cytochromes P450 is initiated by 
substrate-binding to a low-spin ferric “resting state”, which possesses an axial water 
ligand associated with a distal pocket water cluster. Entry of the substrate disrupts the 
water cluster and displaces the bound axial water ligand, generating a high spin ferric 
heme, whose elevated reduction potential triggers acceptance of an electron that, in the 
case of CYP11A1, is provided by NADPH associated adrenodoxin reductase (AdR) and 
delivered by an Fe-S cluster contained in adrenodoxin (Adx). This resultant ferrous 
species binds molecular oxygen present within the immediate environment to form a 
dioxygen adduct, which is most properly formulated as a ferric superoxide species, 
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Fe(III)-(O-O-).2,42 Delivery of another electron from the AdR/Adx reductase ensemble 
then produces a ferric peroxo intermediate, Fe(III)-(O-O2-). While there exist special 
situations where this ferric peroxo species can react directly with electron- deficient 
fragments of a given substrate, generally, it is converted by rapid, sequential delivery of 
two heme pocket protons to first form a transient hydroperoxo- species and then, with the 
delivery of the second proton, undergo efficient O-O bond cleavage to generate an 
extremely potent oxidant, known as Compound I, which is most accurately formulated as 
a ferryl heme π cation radical; i.e., [(Porphyrin+∙) Fe(IV)=O].41,45,68,89–92 This species is 
capable of direct hydroxylation of many types of substrate.93 The first and second steps of 
the 3-stage CYP11A1-catalyzed conversion of cholesterol to pregnenolone are classical 
hydroxylations reasonably assumed to proceed through Compound I.42 The operative 
mechanism for the third step, involving a more elaborate C-C bond cleavage process, is 
still a subject of some debate regarding the details of the Compound I mediated 
transformation.40,94–102 
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Figure 3.1.3 Conversion process from cholesterol to pregnenolone through CYP11A1 
 
Because the F-G loop and A’ helix of CYP11A1 is partially associated with 
membrane, it is not soluble in aqueous solution. Crystal structures with intermediates 
were hard to form until 2011. Strushkevich et al. published a crystal structure of 
adrenodoxin (Adx) bound to CYP11A1 proximal position shown in Figure 3.1.4. Only 
few amino acids of CYP11A1 are associated with the membrane, so the enzyme is not as 
tightly bound with the membrane as those enzymes possessing a substantial hydrophobic 
tail.40 This is consistent with the former model hypothesis. The pocket of the active site is 
a banana-shaped tunnel with volume of the cavity is around 625 A3. The substrate, 
cholesterol, enters the active site pocket from the top opposite with the Adx and the 
product, pregnenolone, leaves the pocket from the top also. The shape and length of the 
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tunnel shows that the substrate movement is translational when the intermediates move 
toward or away from the active site. 
 
Figure 3.1.4 Crystal structure of CYP11A1-Adx complex40 
  
Strushkevich et al40 also published the superposition of active site with cholesterol, 
22R-OHCH and 20R, 22R-DiOHCH, shown in Figure 3.1.5. From the superposition 
figure and the crystal structure, the distance of C22 to the heme Fe is 4.3 Å and that from 
C20 to heme Fe is 4.5 Å. However, modeling indicates that the distance between the 
hydrogen at C22 and the oxyferryl oxygen is 2.3 Å, whereas the hydrogen at C20 is 
slightly away with a distance of 2.6 Å. That explains the reason why the first 
hydroxylation takes place at C22 position to generate 22R-OHCH. After the first cycle, 
the C22 position moves towards the heme-Fe a little compared with C22 in cholesterol. 
This movement brings the H at C20 position closer to the heme-Fe, which allows the 
hydroxylation at C20 position during the second cycle to generate 20R, 22R-DiOHCH. 
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After the second cycle, the whole chain moves back to original position. The heme-Fe 
locates right between the C20 and C22. This position insures the cleavage between C20 
and C22 during third cycle even though the detailed cleavage mechanism still remains 
unknown.  
 
Figure 3.1.5 (left) Superposition of cholesterol and 22R-OHCH above the heme; (right) 
superposition of 22R-OHCH and 20R, 22R-DiOHCH40 
 
Interestingly both Strushkevich et al40 and Mast et al39 published the crystal 
structure of CYP11A1 with substrate 22R-OHCH, which shows almost full low spin in 
ferric state. The most likely reasons are: 1) the water molecule in the active site is still 
bound to the heme Fe as a sixth ligand; 2) the O of the hydroxyl group from the 22R-
OHCH substrate serves as the sixth ligand. Strushkevich et al indicated that continuous 
electron density was observed between Fe and the O from C22 hydroxyl group and the 
distance was 2.6 Å.40 Mast et al also showed the distance was 2.56 Å which was very 
likely a covalent bond.39,59 Further study needs to be done to provide more evidence 
before a definitive conclusion can be reached.51   
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Mast et al39 measured electronic absorption spectra of the ferrous CO form with 
different substrates and without substrate (seen in Figure 3.1.6). The interesting thing is 
that there is no band at around 450nm for CYP11A1 bound with 22R-OHCH; i.e., they 
argue that CO doesn’t bind. The explanation offered for  why this complex apparently 
binds dioxygen, but not CO,  is because of the steric effect; i.e.,the angle of Fe-C-O is 
180º, while the angle of Fe-O-O is only about 108º, allowing the O-O to bind end-on 
without interference by the C-OH fragment of the substrate.39 However, these results are 
surprising in light of the fact that rR and FTIR spectroscopic studies, published years 
before,103 had provided solid evidence for the stability of the Fe-CO adduct of CYP11A1 
bound with 22R-OHCH. As will be discussed below, perhaps the reason the early 
spectroscopic data was not considered definitive was that the data acquired in that work 
yielded interpretations that were somewhat ambiguous (vide infra). 
Of direct relevance to this seemingly conflicting evidence are studies published 
by Tuckey and Kamin,104 who found out that the order of binding affinity of CO to 
CYP11A1 is: substrate free > cholesterol >20(S)-hydroxycholesterol > 22R-OHCH, and 
then 20R, 22R-DiOHCH. The results presented by Tuckey and Kamin verified that CO 
can bind in this case, but has a much lower affinity; i.e., both spectroscopic and 
functional studies had shown that CO was hard to bind with CYP11A1 when 22R-OHCH 
was the substrate.97,100 
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Figure 3.1.6 Reduction of CYP11A1 with sodium dithionite substrate free (black line), 
cholesterol (dashed line), 22HC (red line)39  
  
The previously published resonance Raman studies of CYP11A1 dealt with the 
CO adducts of CYP11A1 bound with different substrates (including 22R-OHCH) and the 
substrate-free form (Figure 3.1.7).98,99 As mentioned above, these workers detected the 
Fe-C stretching frequency for the CO forms with all of the substrates, including  22R-
OHCH, while Mast et al39 had concluded that CO can’t bind with CYP11A1 with this 
latter substrate. On the other hand, though the spectroscopic data confirm CO binding to 
the sample containing the R22-OHCH substrate,98,99 the observed sets of Fe-C and C-O 
stretching frequencies do not adhere to the well-established inverse correlation between 
these two modes.72 Usually high C-O stretching frequency will correspond to low Fe-CO 
stretching frequency,44 but that correlation was not observed here. More importantly, it is 
interesting to note that, in the case of the CO adduct with the R22-OHCH substrate, only 
one ν(Fe-C) stretch was observed, while two ν(C-O) stretches were seen in the FTIR 
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spectrum. For these reasons, new vibrational spectroscopic studies of the these systems 
are carried out in the present work, as will be later presented and discussed.  
 
Figure 3.1.7 CO forms of CYP11A1 bound with different substrates: (1) substrate free; (2) 
cholesterol; (3) 25-OH-cholesterol; (4) 22(R)-OH-cholesterol; (5) 22(S)-OH-cholesterol; 
(6) 20(S)-OH-cholesterol; (7) 20(R),22(R)-dihydroxycholesterol; (8) 22-ketocholesterol. 
Effects of reduced adrenodoxin binding are indicated by arrows. 103 
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Tsubaki et al105 also used resonance Raman to check the effects of adrenodoxin 
and cholesterol. They concluded that with cholesterol only there was only about 70% spin 
conversion from low spin to high spin, but that that after adding of adrenodoxin, there 
was full conversion to high spin. In the spectra shown in Figure 3.1.8, ν10 (1638 cm-1), ν3 
(1503 cm-1) and ν2 (1584 cm-1) are spin state sensitive modes indicating ferric low spin 
state. From those spin state markers, it is argued that the sample in the middle trace is a 
mixture of high spin and low spin, where ν10 shifted to 1620 cm-1, ν2 shift to 1567 cm-1, ν3 
shifted to 1485 cm-1, all indicating high spin. However, it is important to note that, of 
these spin state markers, only the ν3 mode is normally in an isolated region of the 
spectrum and acts as a reliable marker; in the present case the HS component of that 
mode is overlapped by the strong glycerol band present, making evaluation of spin state 
population difficult. Therefore, these studies are to be repeated in the present work, as 
described later. The lower trace, obtained from CYP11A1 with substrate CH and redox 
partner Adx, which was interpreted to show almost high spin, though the presence of 
overlapping modes can hinder an accurate interpretation.  
In the low frequency region, only two Raman peaks are seen at 346 cm-1 and 380 
cm-1, while others are from glycerol. Oxidized adrenodoxin has Raman lines at 289 cm-1, 
346 cm-1 and 381 cm-1. It is hard to tell the structural change upon binding of Adx or 
different substrates from the low frequency data, because the major heme modes are 
obscured by the peaks from the buffer/glycerol media. Glycerol has an effect on 
CYP11A1 spin state conversion. Also, Headlam et al64 have stated that glycerol will tend 
to convert CYP11A1 from high spin to low spin; perhaps this would cancel the effects of  
adding of substrates and adrenodoxin. In the present study, the aqueous buffer will be 
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used to illustrate the effects of CYP11A1 with different substrates with and without Adx 
in the high frequency and low frequency.  
 
Figure 3.1.8 Resonance Raman spectroscopy of CYP11A1 with addition of cholesterol 
and cholesterol+adrenodoxin 105 
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3.1.3 Adrenodoxin (Adx) 2Fe-2S cluster 
Adx is a member of a class of redox proteins, called ferredoxins, which contain a 
[2Fe-2S] cluster. The Adx serves as an electron transport protein that provides electrons 
from a NADPH containing enzyme, adrenodoxin reductase (AdR), to the active site of 
CYP11A1. It has been reported that the inherent reduction potential of substrate-bound 
CYP11A1 is -284 mV, while that for Adx is -273 mV and that protein-protein complex 
formation caused the redox potential of Adx to undergo a small negative shift to -291 mV, 
while that of the CYP11A1 shifted to -312 mV. 106,107 The mechanism of electron transfer 
process is still not entirely clear. There are three main hypothesis: 1) Adx serves as a 
shuttle between AdR and CYP11A1; 2) a 1:1:1 complex of AdR, Adx and CYP11A1 is 
formed; 3)  a 1:2:1 complex of AdR, Adx and CYP11A1 forms.108–111 Although many 
attempts have been made to illustrate the exact mechanism and favor the shuttle model, 
none of these can be definitely ruled out.109 The association of  Adx and CYP11A1 is 
postulated arise from electrostatic interactions of charged surface residues of Adx and 
CYP11A1.109 The recently reported crystal structure of the fusion protein between Adx 
and CYP11A1 revealed the presence of two salt bridges: Lys339 (CYP11A1)-Asp72 
(Adx) and Lys 343 (CYP11A1)-Asp76(Adx). 40 
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3.1.4 NADPH-AdR Adrenodoxin reductase 
Adrenodoxin reductase (AdR) is also called ferredoxin NADP+ (nicotinamide 
adenine dinucleotide phosphate) reductase because AdR can reduce a ferredoxin Adx by 
using the electron provided by NADPH. AdR has a coenzyme flavin adenine dinucleotide 
(FAD) which can accept electron from NADPH and then transfer to Adx. Multiple 
electrons can be transferred but only one at a time.  
3.1.5 Research purpose of CYP11A1 
Resonance Raman (rR) spectroscopy has been applied to study various heme 
proteins and enzymes for decades.71,112 Applications are focused on rR-based 
determinations of: spin population change;113 distortions of the heme, as reflected in 
variations of the in-plane and out-of-plane macrocycle modes; 71,112,114,58,115–118 and 
interactions of the vinyl and propionate groups on the heme periphery, as reflected in the 
behavior of the propionate- and vinyl- bending modes appearing in the low-frequency 
region and the vinyl group ν(C=C) stretching modes that are observed near 1600-1640 
cm-1 and are sensitive to out-of-plane disposition of these groups with respect to the mean 
heme plane.114,119–123 In addition to these rR markers of heme structural changes, the 
technique is an especially powerful and direct probe of the strength of binding of various 
endogenous and exogenous heme axial ligands. For example, the behavior of the ν(Fe-C) 
and ν(C-O) for ferrous CO forms reveal detailed information about the polarity of the 
distal pocket and H-bonding interactions with molecular fragments of bound substrates or 
distal pocket protein residues.72 Of special importance for this work, the ν(Fe-O) and 
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ν(O-O) modes of the oxy form of cytochromes P450 and certain other proteins bearing an 
axial cysteine-thiolate are efficiently rR enhanced and provide telltale vibrational data 
that reflect subtle, but functionally important, H-bonding differences with distal side 
molecular fragments.72,124 Also important for the present application is the fact that rR is 
able to probe the status of the key ν(Fe-S) mode, using 356 nm excitation line, which is in 
close proximity to an SFe(III) LMCT transition occurring near 360 nm.35,114,125–129 
Moreover, rR measurements can monitor the effects of redox partners on the heme active 
sites for all of the above forms. It is also important to mention that rR measurements can 
be done at different temperatures; e.g., near room temperature for samples in natural, 
aqueous conditions (with varying pH and ionic strengths), as well as at cryogenic 
temperatures, under conditions in which unstable intermediates can be characterized. 
Early rR studies of this enzyme were reported mainly by Tsubaki et al., for the 
ferric and ferrous CO states, providing valuable insight,41-43 but also leaving some 
unexplained issues of interpretation unanswered (vide infra). In  the present work we 
expand the rR investigation of CYP11A1 to studies of the dioxygen complexes, 
ordinarily fleeting intermediates within cytochrome P450 reactions cycles at ambient 
temperatures that must be prepared and stabilized under low temperature 
conditions.124,130,131 Studies of such dioxy-intermediates by rR spectroscopy have recently 
been shown to be an especially effective approach to reveal even subtle active site 
structural changes that significantly impact the disposition of crucial intermediates and 
influence alternative reaction pathways that may occur within in these enzymatic 
cycles.124,130 For example, the rR technique can reveal quite subtle, but highly significant 
differences in hydrogen bonding interactions with the Fe-O-O fragment, with H-bonding 
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to the proximal oxygen (Fe-Op) leading to a lower ν(Fe-O)frequency, while H-bonding to 
the terminal oxygen (Fe-Op-Ot) yields relatively higher ν(Fe-O) modes. 72,132 This is quite 
an important capability, because DFT computations,133 as well as studies of the dioxygen 
adducts of NOS,18,134,135 have indicated that  hydrogen bonding to the proximal oxygen 
will stabilize this intermediate, thereby the hindering cleavage of the O-O bond, making 
it more likely that a (susceptible) substrate will be processed through the peroxo 
intermediate.124,133 On the other hand, if hydrogen bonding is formed to the terminal 
oxygen atom of the Fe-O-O fragment, which favors the breakage of the O-O bond,136,137 
the reaction inevitably proceeds through the compound I intermediate.130,133 
The original purpose of this project is to evaluate the activity of CYP11A1 with 
its natural substrates bound with redox partner Adx in nano-disc system in order to avoid 
the aggregation. Since the difficulty of collaboration, the results presented here is the 
CYP11A1 without nano-disc. CYP11A1 only have a few amino acids associated with the 
membrane so the aggregation is not a big issue during our experiments.40 Detailed task 
was listed below. 
1) Measure CYP11A1 ferric forms bound with its three natural substrates and 
their Adx effect; 
2) Evaluate the proximal ligand effect by measuring the Fe-S linkage; 
3) Stable ligation forms with CO of all three natural substrates and their Adx 
effect; 
4) FTIR measurements with CYP11A1 bound with 22R-OHCH and 20R,22R-
DiOHCH in ferrous CO form; 
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5) Most importantly, characterize the unstable intermediates oxy-forms and their 
Adx effect to predict the active catalysis during the hydroxylation cycles. 
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3.2 Methods and experiments 
3.2.1 Bovine CYP11A1 purification 
Fresh bovine adrenal glands were purchased from a local slaughter house and the 
connective tissue and fat was removed as much as possible. CYP11A1 is in the adrenal 
cortex which is a brownish layer between medulla (core part) and the capsule (skin part). 
Adrenal cortex was scraped by a scalpel to very small pieces. This material was then 
chopped to form a fine mash in order to obtain a successful homogenization. The adrenal 
cortex was suspended in 4 volumes of cold 0.25 M sucrose solution containing 10 mM 
phosphate pH 7.4, 0.1 mM ethylenediaminetetraacetic acid (EDTA) and 0.1 mM 
dithiothreitol (DTT). The homogenate was centrifuged (4℃) at 500xg for 10 minutes to 
remove the unbroken cells and nuclei. The supernatant was centrifuged again at 11,000xg 
for 30 minutes at 4℃, forming a brown pellet (called mitochondrial pellet), which 
were collected and stored.  
The mitochondria pellets were resuspended in 20 mM phosphate buffer pH 7.5 
containing 0.10 mM EDTA and 0.10 mM DTT. This solution was homogenized to fully 
mix. The solution was sonicated for 1 minute, using two 30 second bursts, with a 5 
minute interval between bursts. The sonicated suspension was centrifuged at 100,000xg 
for 1 h at 4 ºC, using an ultracentrifuge (Beckman Coulter, OptimaTM L-90K 
ultracentrifuge). The supernatant, which contains adrenodoxin and adrenodoxin reductase, 
was stored. The Adx purification will be described in next section. The pellets, which are 
called sub-mitochondrial particles, were re-suspended by homogenization in 100 mM 
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phosphate buffer pH7.4, containing 0.1 mM EDTA and 0.1 mM DTT. The protein 
concentration was checked by using Bradford assay138 and diluted to a concentration of 
15 mg/ml. The suspended sub-mitochondrial particles were extracted for 1 h with 1% 
cholate by adding 10% sodium cholate stock dropwise while stirring. The cholate 
containing solution was centrifuged at 100,000xg for 1 h at 4℃ by using an 
ultracentrifuge. The supernatant which contains CYP11A1 and CYP11B1 was kept.  
The volume of the supernatant was measured. The 18 g of the ammonium sulfate 
(NH4)2SO4 per 100 ml supernatant was added for 0 - 32% saturation. The (NH4)2SO4 was 
added slowly while stirring and making sure all (NH4)2SO4 is dissolved. The solution 
stood for 30 minutes. The solution was centrifuged at 50,000xg for 10 minutes at 4℃. 
Discard the pellet which contains CYP11B. The volume of supernatant was measured. 
The 8 g ammonium sulfate was added per 100 mL of supernatant for 30 - 45% saturation, 
dissolve and stand for 30 minutes and centrifuge the solution at 50,000xg for 10 minutes 
at 4℃. The pellets were resuspended in 100 mM phosphate buffer pH7.2 containing 0.1 
mM EDTA and 0.1 mM DTT and dialysis in this buffer for overnight.  
After dialysis, the solution was centrifuged at 12000 rpm for 20 minutes at 4℃ to 
remove the undissolved or denatured protein. An Octyl sepharose column was 
equilibrated by washing with 100 mM phosphate buffer pH7.2 containing 0.1 mM EDTA 
and 0.1 mM DTT. The clear solution was loaded on the column and washed with the 
equilibrated buffer until no color elutes. Then the column was washed with 100 mM 
phosphate buffer pH7.2 containing 0.03% cholate, 0.5M KCl, 0.1 mM EDTA and 0.1 
mM DTT until no color elutes and the major fraction was not eluted. The CYP11A1 was 
eluted by 100 mM phosphate buffer pH7.2 containing 0.3% cholate, 0.5M KCl, 0.1 mM 
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EDTA and 0.1 mM DTT. The product was collected in fractions and checked by UV. 
Fractions with absorption of A390nm / A280nm greater than ~0.6 were pooled as pure 
CYP11A1. The pure samples were dialysis overnight at 100 mM phosphate buffer pH7.2 
containing 0.1 mM EDTA and 0.1 mM DTT in order to remove cholate and extra salt. 
The sample was measure by UV to check the concentration and its CO form to check the 
P420 amount. Then the sample was diluted and divided into small vials and stored at -80℃ 
for future use.  
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3.2.2 Bovine adrenodoxin purification 
A DE52 column, equilibrated with 100 mM phosphate buffer pH7.4 containing 
0.1 mM EDTA and 0.1 mM DTT, was prepared. The sub-mitochondrial supernatant 
containing the Adx and AdR, saved in section 3.2.1, was loaded to the column. The 
brown Adx binds to the top of the gel. The AdR, and other proteins, were eluted from the 
column with the 100 mM phosphate buffer, pH7.4 containing 0.1 mM EDTA and 0.1 
mM DTT until no color elutes. The unwanted proteins were eluted through different 
buffers listed below. Then the column was washed with 200ml 10 mM phosphate buffer 
pH 7.4 containing 0.1 M KCl. The column was then washed with 200mL of 10 mM 
phosphate buffer pH 7.4 containing 0.12 M KCl. The column was washed with 200mL 
10 mM phosphate buffer pH 7.4 containing 0.15 M KCl until the Adx band moves to the 
bottom of the gel. The Adx was eluted with 10 mM phosphate buffer pH 7.4 containing 
0.3 M KCl. The product was collected in fractions, check UV, pooling the fractions with 
absorption of A414/A280 larger than 0.1.  
A new DE52 column equilibrated with 100 mM phosphate buffer pH7.4 was 
prepared. The above samples were diluted three times and loaded on the column. The 
column was washed with 100 mM phosphate buffer pH7.4. The column was washed with 
200mL 10 mM phosphate buffer pH 7.4 containing 0.1 M KCl. The column was washed 
with 200mL 10 mM phosphate buffer pH 7.4 containing 0.15 M KCl until the Adx band 
moved to the bottom of the gel. The Adx was eluted with 10 mM phosphate buffer pH 
7.4 containing 0.3 M KCl. The product was collected in fractions, checked by UV, and 
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the fractions with absorption of A414/A280 larger than 0.4 were pooled. The samples were 
concentrated to approximate 4-5 ml for next step. 
A 2 cm x 70 cm long column was prepared with gel Sephadex G100 in 100 mM 
phosphate buffer pH7.4. The samples collected from previous step were applied on the 
column. Slowly Adx moved down in the column and collected 2-3 mL fractions. The 
fractions were checked by UV and the fractions with absorption of A414/A280 larger than 
0.7 were pooled. The sample was concentrated and divided them in small amount and 
store at -80℃ for future use. 
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3.2.3 Preparation of ferric samples 
The CYP11A1 purified from bovine adrenal glands naturally binds with 
cholesterol which gives majority of high spin. Since the binding affinity of the other two 
substrates, 22R-OHCH and 20R,22R-DiOHCH, are much higher than cholesterol, 
different substrates binding samples were made by adding from ethanol stock solution 
with 3-5 fold excess and incubated overnight to insure the fully exchange. The ratio of 
Adx to P450scc is 1.2:1 for those Adx containing samples. The samples containing redox 
partner were incubated overnight in order to insure the full binding of Adx. The 
concentration of all the ferric samples measured by excitation line 406.7 nm is 100 uM of 
CYP11A1 in buffer 100 mM phosphate buffer pH 7.4, 0.1 mM DTT and 0.1 mM EDTA. 
CH bound with CYP11A1 ferric sample: dilute or concentrate the sample to 100 
uM concentration; 
CH bound with CYP11A1 containing Adx ferric sample: incubate purified 
CYP11A1 with 20% excess amount of Adx for overnight. Then concentrate the sample to 
100 uM concentration of CYP11A1.  
22R-OHCH bound with CYP11A1 ferric sample: add 3-5 fold excess amount of 
22R-OHCH from ethanol stock solution with purified CYP11A1 and dilute the solution 
to lower the ethanol concentration be less than 1%. Incubate this solution for overnight 
then centrifuge to remove the denatured protein. Concentrate the sample to 100 uM. 
22R-OHCH bound with CYP11A1 containing Adx ferric sample: add 3-5 fold 
excess amount of 22R-OHCH from ethanol stock solution and 20% excess amount of 
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Adx with purified CYP11A1. Dilute this solution to lower the ethanol concentration be 
less than 1%. Incubate this mixture for overnight then centrifuge to remove the denatured 
protein. Concentrate the sample to 100 uM. 
20R,22R-DiOHCH bound with CYP11A1 ferric sample: add 3-5 fold excess 
amount of 20R, 22R-DiOHCH from ethanol stock solution with purified CYP11A1 and 
dilute the solution to lower the ethanol concentration be less than 1%. Incubate this 
solution for overnight then centrifuge to remove the denatured protein. Concentrate the 
sample to 100 uM. 
20R, 22R-DiOHCH bound with CYP11A1 containing Adx ferric sample: add 3-5 
fold excess amount of 20R, 22R-DiOHCH from ethanol stock solution and 20% excess 
amount of Adx to purified CYP11A1. Dilute this solution to lower the ethanol 
concentration be less than 1%. Incubate this mixture for overnight then centrifuge to 
remove the denatured protein. Concentrate the sample to 100 uM. 
The only samples used to investigate the behavior of the ν(Fe-S) of the ferric 
forms, measured by excitation line 356.4 nm, were those bound with CH, with and 
without Adx. The preparation was the same as described above. The concentration is 200 
uM in 10 mM phosphate buffer pH 7.4, 0.1 mM DTT and 0.1 mM EDTA, because in this 
lower buffer condition there is more difference for the Adx effect in high spin population.  
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3.2.4 Preparation of the ferrous-CO samples 
3.2.4.1 Ferrous-CO samples for rR 
Regarding preparation of the various ligated forms, the ferrous CO adducts were 
made by addition of an excess amount of reducing agent, sodium dithionite (Na2S2O4), 
from stock solution. A 100 µL aliquot of a 100 µM sample of the enzyme was placed in 
an NMR tube (WG-5 Economy,Wilmad) and sealed with a rubber septum (Sigma-
Aldrich, Milwaukee, WI). The tube was connected to a vacuum line with a needle 
connection. The sample was degassed three times by exchange with Ar gas and then 
exchanged with CO gas two times to ensure the sample was saturated by CO gas. A 
freshly prepared solution of sodium dithionite dissolved in an Ar degassed buffer was 
added to the solution of CYP11A1. The ferric sample can be reduced by addition of ~2 
molar equivalents of sodium dithionite solution (8 µL). The electronic absorption 
spectrum (Q-band region) showed a sharp band rising at ~550 nm and a disappearing 
band at ~645 nm; the solution was allowed to incubate for 15 minutes to ensure full 
conversion. 
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3.2.4.2 Ferrous-CO samples for FTIR 
 
Ferrous-CO adducts for FTIR measurements are only made with 22R-OHCH and 
20R, 22R-DiOHCH-bound CYP11A1. Making the ferric form of 22R-OHCH and 20R, 
22R-DiOHCH bound CYP11A1 was described in section 3.2.3. The samples were 
concentrated to higher than 200 uM since FTIR needs higher concentration to get better 
signal-to-noise. The ferrous CO samples were made by adding an excess amount of 
Na2S2O4 to the CO saturated ferric sample in 2 ml glass vial sealed with rubber septum 
and then incubated for 15 minutes to ensure full conversion to ferrous CO. Then the 
ferrous CO sample was transferred, as quickly as possible, to the FTIR cell, which had 
already been flushed with CO gas. The concentration of the protein for FTIR sample was 
200-300 µM. 
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3.2.5 Preparation of the oxy samples 
Oxy samples were prepared on the vacuum line. The oxygenated samples were 
prepared from the ferric samples as described in the following manner. A 100 µL aliquot 
of concentration at 200 µM ferric CYP11A1 sample was placed in the NMR tube and 
connected to the vacuum line. The sample was degassed with Ar gas by evacuating the 
air out of the tube and filling Ar gas into the tube, repeating the process three times to 
make sure the sample was saturated with Ar gas but no oxygen present. Sodium 
dithionite, freshly made in Ar degassed the buffer, was added to the solution by using a 
gas sealed syringe through a rubber septum on the vacuum line system into the ferric 
sample, gently tapping the sample to mix well. The sample was titrated with small 
amounts of sodium dithionite solution while monitoring the rising the sharp band at ~550 
nm and the disappearing band at ~645 nm. Then oxygen can be added to this ferrous 
sample by bubbling 16O or 18O gas, using vortex to spin the sample in order to mix well 
and let the oxygen bind with the complex well. The sample was placed in the cold bath 
temperature at 0  ̊C. The mixing time is different according to the substrates; the oxygen 
complexes of the samples with the first two substrates, CH and 22R-OHCH, were 
prepared using 30 seconds mixing time, while the sample containing  20R, 22R-DiOHCH 
was mixed for 90 seconds. The oxygenated samples were frozen in the liquid N2 
immediately after mixing to avoid auto-oxidation.  
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3.2.6 Spectroscopy with CYP11A1 
3.2.6.1 Resonance Raman with ferric samples at room temperature 
Ferric CYP11A1 samples were measured using the 406.7 nm and 356.4 nm 
excitation lines from a Kr+ laser (Coherent Innova Sabre Ion Laser). The rR spectra of all 
samples were collected using a Spex 1269 spectrometer equipped with Spec- 10 LN-
cooled detector (Princeton Instruments). The slit width was set at 150 μm, and the 1200 
g/mm grating was used; with this grating, the resultant spectral dispersion is 0.46 
cm−1/pixel. The laser power for the ferric sample was adjusted to ∼10 mW. Moreover, to 
avoid laser-induced heating and protein degradation, the samples were contained in 
spinning NMR tubes (5 mm outside diameter, WG-5 ECONOMY, Wilmad). The 180° 
backscattering geometry was used for all measurements, and the laser beam was focused 
onto the sample using a cylindrical lens. Ferric samples were measured at room 
temperature. Fenchone was used to calibrate the spectrum processed by Grams. Rayleigh 
scattering was removed by Notch filter.  
Two sets of samples having different buffer conditions were prepared: (1) 100 
mM phosphate buffer pH 7.4 containing 0.1 mM DTT and 0.1 mM EDTA; (2) 10 mM 
phosphate buffer pH 7.4 containing 0.1 mM DTT and 0.1 mM EDTA. There were 24 
samples prepared according to the buffer condition, substrates and Adx effect. All the 
ferric samples were measured using 406.7 nm, close to the maximum absorption, and 
were scanned for 60 minutes in low frequency region and 30 minutes for high frequency 
region.  
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Only two sets of samples were measured by 356.4 nm: CYP11A1 bound with CH 
with and without Adx in 10 mM phosphate buffer pH 7.4 containing 0.1 mM DTT and 
0.1 mM EDTA. The ferric samples measured by 356.4 nm were scanned for 60 minutes. 
Since the electronic transition between the heme Fe and S of the proximal amino acid 
cysteine occurs at ~360 nm, the excitation line 356.4 nm was used to monitor the effect 
of Adx binding.  
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3.2.6.2 Resonance Raman spectra of ferrous-CO samples at room temperature 
 
The Fe(II)-CO adducts were excited by the 441.6 nm line provided by a He-Cd 
laser (IK Series He Cd laser, Kimmon Koha CO., Ltd.). The rR spectra of all samples 
were collected using a Spex 1269 spectrometer equipped with Spec- 10 LN-cooled 
detector (Princeton Instruments). The slit width was set at 150 μm, and the 1200 g/mm 
grating was used; with this grating, the resultant spectral dispersion is 0.46 cm−1/pixel.  
The laser power for the ferrous CO adducts was kept at ∼1 mW to minimize 
photodissociation. Moreover, to avoid laser-induced heating and protein degradation, the 
samples were contained in spinning NMR tubes (5 mm outside diameter, WG-5 
ECONOMY, Wilmad). The 180° backscattering geometry was used for all measurements, 
and the laser beam was focused onto the sample using a cylindrical lens. Ferrous CO 
samples were measured at room temperature. These conditions are the same as measuring 
ferric samples except the power.  
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3.2.6.3 FTIR measurements of the ferrous-CO samples 
 
The infrared spectra were obtained using a 4020 Galaxy Series FT-IR 
spectrometer, Matson Instruments. The Wilmad semi-permanent cell (IR OTTLE33) 
purchased from New Era, when equipped with a Teflon spacer with 0.1 mm width placed 
between two CaF2 windows, requires only 60 uL of sample for each measurement. The 
infrared spectrophotometer was run in a single-beam mode. A spectrum was acquired 
with no sample cell present (i.e., air) to serve as a blank and then 6 scans of a ferric 
sample (each with 500 acquisitions) were collected; the same procedure was used for 
collection of the ferrous-CO samples. The presented data are the difference spectra 
between the ferrous-CO and ferric samples. 
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3.2.6.4 Resonance Raman spectra of the oxy samples 
 
Multiple excitation lines, including the 356.4, 406.7 and 415.4 nm lines from a 
Kr+ laser (Coherent Innova Sabre Ion Laser), as well as the 441.6 nm from the He-Cd 
laser, were employed to try to enhance the ν(Fe-O) and ν(O-O) modes of the oxy samples, 
but adequate signal to noise ratios were obtained for these modes only when using the 
415.4 nm and 441.6 nm lines. The rR spectra of all samples were collected using a Spex 
1269 spectrometer equipped with Spec- 10 LN-cooled detector (Princeton Instruments). 
The slit width was set at 150 μm, and the 1200 g/mm grating was used; with this grating, 
the resultant spectral dispersion is 0.46 cm−1/pixel. The laser power for oxy samples was 
kept at ∼1.0 mW minimize photodissociation. Moreover, to avoid laser-induced heating 
and protein degradation, the samples were contained in spinning NMR tubes (5 mm 
outside diameter, WG-5 ECONOMY, Wilmad). The 180° backscattering geometry was 
used for all measurements, and the laser beam was focused onto the sample using a 
cylindrical lens to form a line image. The oxy samples were measured at 77K, employing 
an in-house designed immersion dewar, fitted with a NMR tube sample spinning device. 
Spectra were calibrated with fenchone (Sigma-Aldrich, WI), and processed with 
Grams/32 AI software (Galactic Industries, Salem, NH). Conditions to measure oxy 
samples are almost the same except temperature.  
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3.3 Results and discussion 
While the large majority of Cytochrome P450 mediated oxidations proceed 
through the Compound I intermediate arising from proton-assisted O-O bond cleavage of 
the precursor ferric peroxo- species, any conditions which effectively restrict protonation 
of the latter can facilitate its attack on susceptible bound substrates.16,18,139,140 Indeed, rR 
evidence has been recently obtained for H-bonded proximal oxygen of the (Fe-Op-O) 
fragment, which supports this mechanism in the case of the C-C bond cleavage reaction 
that occurs for 17-hydroxy-pregnenolone (17-OH PREG) processing by CYP17A1;34on 
the other hand, the rR confirmation of a H-bond interaction with the terminal oxygen of 
the Fe-O-Ot fragment disfavors such a mechanism for the C-C bond 
cleavage/aromatization process that occurs for CYP19 production of estrone and suggests 
the mediation of the Compound I species,44 a conclusion which is in essential agreement 
with very recent kinetic studies by Sligar and coworkers.141 Given that rR spectroscopy 
provides an effective probe of these functionally important H-bonding interaction with 
the Fe-O-O fragments of dioxy intermediate, it has herein been used to probe the 
dioxygen complexes obtained for CYP11A1 bound with each of its three natural 
substrates, CH, 22R-OHCH and 20R,22R-DiOHCH. Before proceeding to a discussion of 
the results obtained for the dioxygen adducts, rR studies undertaken to further define 
active site structural differences that exist for the ferric and ferrous CO-bound forms with 
each of these three substrates present and upon interaction with Adx are presented, these 
additional studies helping to clarify certain nebulous or incomplete results reported in 
previous studies and more clearly defining the effects of substrate and reductase binding 
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on the heme structure and its interactions with active site structural elements, including 
the critical Fe-S linkage between the heme and proximal heme pocket. 
3.3.1 UV of purified CYP11A1 and its CO forms 
The CYP11A1 was purified from adrenal glands. The procedure was described in 
section 3.2.1, pooling the fractions with absorption A394/A280 larger than 0.7. The 
electronic absorption spectrum of purified CH-bound CYP11A1 and its complex with 
Adx are shown in Figure 3.3.1. The red line is for CYP11A1 bound with CH complex 
which shows two bands at 394 nm and 413 nm. This indicates that this complex is only 
partially high spin (band at 394 nm), with the low spin shown at 413 nm. After addition 
of Adx, the band at 413 nm disappeared and gave a relatively wider band at 394 nm 
which indicated the increasing of high spin population compared without Adx complex. 
 
Figure 3.3.1 UV spectrum of purified cholesterol bound CYP11A1 with and without Adx. 
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 In order to estimate the amount of P420 in this purified CYP11A1, the sample 
was reduced by adding Na2S2O4 and bubbling CO in the solution. The results are shown 
in Figure 3.3.2. As can be seen, the intensity of 420 nm band is smaller when compared 
with 450 nm band. This indicated that there was some amount P420 generated during the 
purification process. However, it is emphasized that for most rR measurements, the 
contributions of P420 the the spectra is minimized by using excitation lines in resonance 
with the P450 (e.g., 442 nm). 
The concentration of CYP11A1 was measured by UV-Vis absorption 
spectroscopy on ferrous-CO spectra using reduced form as reference. The difference 
between the absorbance measured at 450 nm and 490 nm of the absorption spectra was 
used to calculate the concentration, based on the reported differential extinction 
coefficient 91 cm-1 mM-1. 64 
 
Figure 3.3.2 UV spectra of ferrous-CO CYP11A1 bound with cholesterol 
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3.3.2 Electronic absorption spectra of CYP11A1 bound with 22R-OHCH and 
20R, 22R-DiOHCH and their Adx effect 
CYP11A1 purified from Adrenal glands are naturally bound with CH, which 
showed the high population of high spin. Because the binding affinity of 22R-OHCH and 
20R, 22R-DiOHCH with CYP11A1 are four times higher  than CH with CYP11A1,142 
the addition of other substrates can be made by incubating the substrate with naturally 
CH bound CYP11A1. The detailed procedure was described in previous section.  
 
Figure 3.3.3 UV spectra of CYP11A1 + 22R-OHCH (red) and CYP11A1 + 22R-OHCH +Adx 
(Black) 
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The electronic absorption spectra of CYP11A1 bound with 22R-OHCH with and 
without Adx are shown in Figure 3.3.3. As can be seen, 22R-OHCH gave almost 100% 
of low spin with and without Adx. This finding means the exchange was successful and 
sufficient. The addition of Adx sample has lower intensity at 415 nm which indicates that 
the addition of Adx will affect the CYP11A1 complex even for this low spin substrate. 
This finding is confirmed by our resonance Raman data in section 3.3.4. 
 
Figure 3.3.4 UV spectra of CYP11A1 + 20R, 22R-OHCH (red) and CYP11A1 + 20R, 22R-
OHCH +Adx (black) 
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The electronic absorption spectra of CYP11A1 bound with 20R, 22R-OHCH with 
and without Adx are shown in Figure 3.3.4. As can be seen, 20R, 22R-OHCH gave 100% 
of high spin, showing only one band at 394 nm. This finding means the exchange was 
successful and sufficient compared with the electronic absorption spectrum of the 
original protein, CYP11A1 + CH complex. After addition of Adx, the intensity of 394 nm 
band is a little lower and narrower than the one without Adx. Situation here is 
complicated to judge which has more high spin population because both the increase 
intensity of 394 nm and narrower band width indicate the increasing of high spin 
population. Additional information about the spin population will be provided by 
resonance Raman in section 3.3.4.  
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3.3.3 Electronic absorption of purified Adx 
The Adx was purified from the adrenal glands along with CYP11A1. The detailed 
procedure was described in section 3.2.2. The fractions with absorption ratio of A414/A280 
larger than 0.7 were pooled as pure samples. The electronic absorption spectrum of pure 
Adx is shown in Figure 3.3.5. The concentration of Adx is calculated based on the 
extinction coefficient 11 cm-1 mM-1 at 414 nm. 
 
Figure 3.3.5 UV spectrum of purified Adx from bovine adrenal glands 
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3.3.4 Resonance Raman of ferric samples 
Early rR studies of this enzyme were reported mainly by Tsubaki et al., for the 
ferric and ferrous CO states, providing valuable insight.103,143,105 However, the 
interpretations of some of these data were hampered by the presence of strong glycerol 
bands that overlap with some heme rR modes, especially in the low frequency region. 
Another troubling issue occurred with the ferrous CO adducts, where it was reported that 
the rR spectrum of  the 22R-OHCH bound sample contained only one ν(Fe-C) stretching 
frequency, while the IR data clearly revealed the presence of two ν(C-O) stretching 
modes, the most reasonable explanation of this unexpected behavior being unintentional 
photodissociation during the Raman experiment.  In this work attempts are made to 
clarify the interpretation of the vibrational spectra of the ferric and ferrous CO adducts 
for all three physiologically important substrates and to further evaluate the effect of Adx 
binding to the CYP11A1 adducts. 
Compared with previous data, the data presented below was acquired from 
samples prepared in aqueous condition without glycerol, ethylene glycol or detergent, all 
of which were contained in previous work and complicated the interpretation by the 
presence of the additives’ Raman bands in both the low frequency and high frequency 
regions; e.g., a high intensity and wide glycerol band appearing at ~1467 cm-1 interferes 
with the ν3 HS at around 1484 cm-1, 103,143,105 an overlap that directly leads to the wrong 
interpretation of the spin population.  
Now turning attention to the newly acquired data, the rR spectra of ferric 
CYP11A1 samples with CH, 22R-OHCH and 20R, 22R-DiOHCH substrates in high and 
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low frequency regions, as well as in the presence of the natural redox partner, 
adrenodoxin (Adx), are shown in Figure 3.3.6. The high frequency spectra were 
normalized to the ν4 mode at 1370 cm-1 and the low frequency region was normalized to 
the ν7 mode at around 674 cm-1 ; neither of these strong modes are included in these 
traces so as to allow a clearer presentation of the lower intensity structure-sensitive heme 
modes. The assignments of the modes were done according to the previous published 
data on cytochromes P450s and model compounds of Ni-octaethylporphyrin.71,112  
High frequency region: The spectra of cholesterol (CH) bound samples (Figure 
3.3.6 A, right panel) show components associated with both the high (HS) and low spin 
(LS) states. The population of high spin state is larger than the LS as seen by higher 
intensity of the high spin markers ν3 at 1484 cm-1, ν2 at 1567 cm-1 and ν10 at around 1621 
cm-1 as compared to the corresponding low spin makers, which are seen at 1500 cm-1, 
1581 cm-1 and 1637 cm-1, respectively. It is noted that the HS ν10 mode overlaps with the 
vinyl stretching modes that are seen more clearly in the spectrum of LS.58  Binding of 
22R-OHCH induces almost complete low spin state conversion as seen by the presence 
of the dominant LS state markers ν3 at 1500 cm-1, ν2 ~1582 cm-1, and ν10 at 1637 cm-1. 
The absence of the HS ν10 mode (1637 cm-1) reveals existence of two vinyl stretching 
modes at 1618 and 1627 cm-1, the lower frequency one being usually associated with the 
in-plane conformation of a vinyl group, with the higher frequency one being associated 
with the out-of-plane conformation. The fact that the 22R-OHCH substrate does not 
induce high spin conversion is not surprising, given the fact that the crystal structure of 
CYP11A1 with this substrate shows that there is a large amount of electron density 
between the O atom of the hydroxyl group attached to the 22 carbon of the substrate and 
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the heme Fe, with the distance between O and Fe being only 2.56 A, indicative of a 
covalent bond between heme iron and substrate; i.e., the presence of six coordinated, low 
spin state, in agreement with observed here rR data.39,40 On the other hand, binding of 
20R,22R-DiOHCH induces a mixture of spin states similar to, but slightly larger, than 
that seen for CH-bound sample (Figure 3.3.6 E). The stated spin state populations for all 
three enzyme/substrate complexes were calculated using previously published HS/LS 
cross section ratios for cytochromes P450.113 Here it was found that the sample isolated 
with CH bound is 63 % HS, the sample prepared with 22R-OHCH is only 8 % HS and 
sample prepared with 20R,22R-DiOHCH is 76 % HS. The detail information will be 
addressed later. 
Low frequency region: The low frequency spectrum of CH-bound sample (Figure 
3.3.6 A, left panel) shows the presence of the propionate bending mode at 379 cm-1 and 
vinyl bending mode at 420 cm-1. Addition of 22R-OHCH substrate to CYP11A1 causes 
activation of an additional propionate bending mode at 363 cm-1, a frequency which is 
generally interpreted to signal the presence of a propionate group now experiencing a 
weaker H-bonding interaction with active site fragments (i.e., amino acid residues, water 
or possibly substrate fragments). Moreover, a small band appearing at 396 cm-1 was also 
enhanced and can be reasonably associated with weak activation of an in-plane vinyl 
bending mode. The presence of two vinyl bending modes associated with in-plane (396 
cm-1) and out-of-plane (420 cm-1) vinyl group conformations in the low frequency region 
of the rR spectrum of the 22R-OHCH-bound sample is consistent with the presence of 
two vinyl stretching modes in the high frequency region assigned to the in-plane and out-
of-plane orientations of vinyl groups, as was discussed above (Figure 3.3.6 C). The 
109 
 
 
 
binding of the third substrate (Figure 3.3.6 E, left panel) shows a spectral pattern quite 
similar to the CH-bound samples.   
 
Figure 3.3.6 Ferric form for different substrates in buffer 100 mM phosphate buffer 
pH=7.4, 0.1 mM DTT and 0.1 mM EDTA. Excitation line 406 nm, acquisition time 60 
mins for low frequency and 30 mins for high frequency at room temperature.  
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CYP11A1 bound with 22R-OHCH: CYP11A1 bound with substrate 22R-OHCH 
shows low spin population which is similar with type II inhibitor binding. The distance of 
Fe and the oxygen in C22 carbon is 2.6 A which is a very weak interaction and long bond 
distance compared with the bond length of covalent Fe-O that is 1.8 A and the distance 
for type II inhibitor of Fe-N is 2.2 A.39 Also the redox potential of CYP11A1 bound with 
22R-OHCH is similar with that bound with CH and 20R, 22R-DiOHCH. The former on 
is -285 mV and later two are -282 mV and -270 mV.107  
Different ionic strength affect to spin population: When lower the ionic strength 
to 10 mM phosphate buffer pH 7.4, 0.1 mM EDTA and 0.1 mM DTT. Data are not 
shown because they are very similar with the listed ones. By using the cross section 
number found in section 2 which is IHS/ILS=1.25, I calculated the spin population in high 
spin percentage are listed in table 3.3.1. From the table, it is easy to see that after addition 
of Adx, the high spin population has increased for all three substrates and in both buffer 
conditions. Compared with the results in two buffers, the Adx brought more high spin 
population changes in the low ionic strength buffer because the high ionic strength buffet 
tends to push more substrates into the active site. Because of this finding, the strength of 
Fe-S linkage was measured in low ionic strength buffer.  
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Table 3.3.1 High spin population in percentage of HS effect of CYP11A1 with different 
substrates, w/o Adx and ionic strength 
        resonance Raman  (%HS)  
CYP11A1+substrate   Adx    100 mMa   10 mMb   
CH 
- 63 58 
+ 73 73 
22R-OHCH   
- 8 7 
+ 13 6 
20R,22R-DiOHCH   
- 76 72 
+ 82 85 
Note: a) 100 mM phosphate buffer containing 0.1 mM EDTA and 0.1 mM DTT; b) 10 mM 
phosphate buffer containing 0.1 mM EDTA and 0.1 mM DTT. 
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The iron-sulfur linkage: Obviously, the nature of the linkage between the heme 
prosthetic group and a given associated protein is quite important for dictating the 
reactivity patterns of the enzyme. 144–146 Indeed, the Fe-S linkage of cytochromes P450 
and some related enzymes plays a key role in enabling these enzymes to mediate such 
remarkable chemical transformations under normal physiological conditions.2,2 
Fortunately, it has been well established that rR spectroscopy, when employing a near 
UV excitation wavelength (e.g., near 350-360 nm), is one of the most effective probes of 
the status of this key Fe-S fragment, providing an easily identifiable ν(Fe-S) band in the 
low frequency rR spectrum.35 Specifically, the behavior of this mode can be documented 
to evaluate the linkage between the heme Fe and the endogenous cysteine thiolate ligand, 
the strength of which can be modulated by structural alterations within the proximal 
heme pocket, the most effective perturbations arising by interaction with natural 
reductases, such as Adx, that typically bind to the proximal side of the active site.  
While several studies have consistently shown that the precise structure of 
substrates, all of which bind within the distal pocket of cytochromes P450, have little or 
no effect on the Fe-S linkage, 129,130,147,148 it is anticipated that interactions with 
reductases can impact the status of the Fe-S linkage. Results from the present work are 
shown in Figure 3.3.7, where the ν(Fe-S) is observed at 347 cm-1 for CYP11A1 bound 
with CH, with no detectable change being seen upon binding Adx. This is an unexpected 
result inasmuch as significant effects on the ν(Fe-S) mode are commonly seen for these 
types of interactions; i.e., binding of putidaredox to P450cam caused a strengthening  of 
Fe-S, as witnessed by an up shift of ν(Fe-S) by ~3 cm-1.148 In addition, a differential effect 
on the Fe-S bond was seen in CYP2B4 interactions with Cyt b5 vs CPR. 129 
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Figure 3.3.7 Low frequency RR spectra of ferric cholesterol bound CYP11A1 w/o Adx in 
buffer 10 mM phosphate buffer pH 7.4, 0.1 mM DTT and 0.1 EDTA. Excitation line 
356.4 nm, acquisition time 60 mins at room temperature. 
 
  
114 
 
 
 
3.3.5 Ferrous-CO samples measured by resonance Raman and FTIR 
Resonance Raman spectroscopic interrogation of the ferrous CO adducts of heme 
proteins has now long been established as an effective probe of proximal-  and especially 
distal-pocket active site structure, with the internal modes of the Fe-C-O fragment 
reporting on th strength of the Fe-L linkage with the trans-axial proximal ligand and 
simultaneously reflecting steric and polar interactions with distal pocket residues, 
including those presented by enzyme-bound substrate,63,72,114,129,147,149–153 the latter 
interaction being crucially important for cytochromes P450, such as the CYP11A1 being 
studied here. Basically, increases in the degree of dπ(Fe) to CO(π*) back-bonding in the 
Fe-C-O fragment, arising from weakening of the Fe-L bond or increases in positive 
polarity of the distal pocket environment, strengthen the Fe-C bond while simultaneously 
weakening the C-O bond, resulting in a negative correlation between the ν(Fe-C) and 
ν(C-O) vibrational modes.72,149–151 In order to provide a more thorough characterization 
of the structural factors involved in CYP11A1 function, such studies have been 
conducted in this work, with a secondary purpose being to try to clarify somewhat 
confusing observations made in previous rR studies of this protein.103 The rR spectra 
acquired for the low frequency region are shown in Figure 3.3.8. 
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Figure 3.3.8 Low frequency RR spectra for CO adducts CYP11A1 with different 
substrates in 100 mM phosphate buffer pH 7.4, 0.1 mM DTT and 0.1 EDTA. Excitation 
line 442.4 nm, acquisition time 60 mins at room temperature. 
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The most obvious finding that is noted upon initial inspection of the data is that 
there are no observable effects of Adx binding upon the status of the Fe-C-O fragment. In 
similar studies reported earlier by other workers,103the changes for Adx binding were 
reported to be quite small (between 0 -1.5 cm-1). However, the apparent existence of 
these small effects, along with the presence of some confusing results of those spectral 
studies, prompted us to reexamine this issue. For example, in those earlier studies it was 
reported that in some cases, including the sample containing the 22R-OHCH, while two 
ν(C-O) modes could be observed by FTIR, only a single ν(Fe-C) could be observed (by 
rR); as will be seen below, these confusing results can be readily explained by the 
presence of unintended photodissociation for the ferrous CO adducts by the rR laser 
excitation beam.  
Now, returning to consider the effects of different substrates on the Fe-C-O 
fragment, the sample bound with cholesterol, a substrate that presents no hydrophilic R-
OH fragments to the bound CO ligand, shows a clear and relatively sharp ν(Fe-C) mode 
appearing at 482 cm-1, a value in good agreement with the previous work,103 and the 
corresponding ν(C-O) being observed in the FTIR spectrum at 1952 cm-1, again a value 
in reasonably good agreement with that reported earlier (i.e., 1954 cm-1).103 In contrast, to 
the relatively simple spectral signature displayed for the CO adduct of the CH-bound 
enzyme, the CO adduct formed for the enzyme bound with the more polar substrate, 22R-
OHCH, whose C22-OH fragment is apparently close enough to the iron binding site to 
have induced a LS spin state by direct interaction with the heme iron, as evidenced in the 
rR data for the ferric state, gave three observed features appearing in the region where the 
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ν(Fe-C) modes are expected to appear: i.e., at 482 cm-1, 500 cm-1 and 515 cm-1.  In order 
to clarify the interpretation of the spectra acquired for the 22R-OHCH substrate, the 
Fe(II)-12C16O and Fe(II)-13C16O samples were made and measured, the results  being 
shown in Figure 3.3.9. From these results, it is clear that both 481cm-1 and 515 cm-1 
bands seen in trace A, shifted down by 5 cm-1 in the spectra of 13C16O isotope, confirming 
their assignments to ν(Fe-C) modes. On the other hand, the feature observed at 500 cm-1 
does not shift upon 12C/13C substitution, securing its assignment to a heme mode. The 
assignment of the 481cm-1 and 515 cm-1 bands to two different Fe-C-O conformers is 
supported by observation two high frequency ν(C-O) modes at 1952 cm-1 and 1934 cm-1 
in the FTIR, as shown in Figure 3.3.10. In previous research,103 the appearance of only 
one band in low frequency was reported for this complex, an observation which may be 
due to accidental photo dissociation perhaps owing to either high laser power (~5 mW) or 
ineffective spinning during the measurement. Indeed, results of experiments to verifying 
photosensitivity for this complex are shown in the bottom two traces of Figure 3.3.9, 
where it is seen there is a strong and wide heme mode overlapped with the ν(Fe-C) modes. 
From previously published data, it was reported that only one ν(Fe-C) mode could be 
detected (at 479 cm-1) for the 22R-OHCH bound CYP11A1 complex; actually this could 
have arisen from a heme mode see at 479 cm-1 in the photo-disassociated sample we 
generated in the present work (Figure 3.3.9 traces C and D).   
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Figure 3.3.9. Isotope effect for 22R-OHCH CO adducts in buffer 100 mM phosphate 
buffer pH 7.4, 0.1 mM DTT and 0.1 EDTA. Excitation line 442.4 nm, acquisition time 60 
mins at room temperature.    
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Figure 3.3.10 FTIR results for high frequency CYP11A1 with substrate 22R-OHCH and 
20R, 22R-DiOHCH ferrous CO forms in 100 mM phosphate buffer pH 7.4, 0.1 mM DTT 
and 0.1 EDTA. 
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Given these clarified spectral traces for the 22R-OHCH-bound ferrous CO adduct, 
the most reasonable conclusion for this species is that this directed C-O-H group interacts 
with the Fe-C-O fragment to produce two different Fe-C-O conformers. Furthermore, it is 
also quite reasonable to conclude that the appearance of two ν(Fe-C) and two ν(C-O) 
modes for the 20R,22R-DiOHCH-bound substrate is also attributable to interactions of 
one or both C-OH groups with the Fe-C-O fragment; indeed, the two pairs of  ν(Fe-
C)/ν(C-O) frequencies are quite similar for both complexes. From this collective data set 
for the three substrates, it seems likely that (for the 2nd and 3rd substrates) the presence of 
one C-OH group positioned quite near the Fe-C-O fragment leads to two Fe-C-O 
conformers, one with a disposition similar to that of the “unperturbed” Fe-C-O conformer 
of the CH-bound enzyme and the other reflecting a reasonably strong H-bonding 
interaction with the C-OH group present on the substrate.  
For all the data described in this section is summarized in Table 3.3.2. Because 
there are no so many data presented here, it is hard to get a linear inverse correlation 
between ν(Fe-C) and ν(C-O) but as can be seen from the table, there is a inverse 
correlationship for a specific substrate complex. The results were clarified compared with 
previous published data. As to evaluate the efficiency of exchange the substrates by 
incubate 22R-OHCH and 20R, 22R-DiOHCH, from the ν(Fe-C) and ν(C-O) data, we see 
the exchange is successful because the totally different pattern.  
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Table 3.3.2 Summary of ferrous- CO CYP11A1 complex with different substrates with 
and without Adx 
        Raman shift (cm-1)  
CYP11A1+substrate   Adx    ν(Fe-C)  ν (C-O) 
CH 
- 482 1952 
+ 482 1952 
22R-OHCH   
- 
482 1952 
515 1934 
+ 
482 nd 
515 nd 
20R,22R-DiOHCH   
- 
482 1954 
510 1934 
+ 
482 nd 
510 nd 
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3.3.6 Resonance Raman of oxy samples 
As was discussed above, recent rR studies of the oxy intermediates of CYP17 and 
CYP19, 34,44 along with analogous studies of NOS,16,18,137,140,154 have shown that this 
technique is effective in detecting subtle structural differences in H-bond interactions 
with the Fe-O-O fragment. Specifically, H-bond donation to the proximal oxygen (Op) of 
the Fe-Op-Ot fragment, which apparently persists upon reduction to the peroxo 
intermediate, stabilizing it for attack on susceptible substrates, exhibits a relatively low 
ν(Fe-O) mode. On the other hand, H-bonding to the terminal oxygen (Ot) of the Fe-Op-Ot 
fragment, which exhibits relatively high ν(Fe-O) frequency, promotes formation of the 
hydroperoxo intermediate, ultimately leading to O-O bond cleavage and Compound I 
formation, an intermediate that effectively mediates the more typical hydroxylation 
reactions. Clearly, the rR technique is an important tool to document these structural 
variations that, though so subtle, carry profound functional consequences.124 Given that 
ambiguity persists regarding details of the C-C bond cleavage process for 20R,22R-
DiOHCH substrate efforts are made here, for the first time, to acquire rR spectra of these 
dioxygen adducts with all three natural substrates, seeking to detect any telltale 
differences in the RR spectra that might reveal H-bonding  differences for the three cases. 
In order to study these relatively unstable oxy-intermediates encountered within the 
catalytic cycles for these three natural substrates of CYP11A1 special procedures were 
required, as summarized earlier in Methods and Materials. Inasmuch as no differential 
effects of the three substrates on the proximal Fe-S linkage were seen in the studies of the 
ν(Fe-S) modes (vide supra),  all effects observed here are presumed to arise from distal 
side structural perturbations.  
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Figure 3.3.11 Oxy samples for all the substrate w/o Adx in 100 mM phosphate buffer 
containing 0.1 mM EDTA and 0.1 mM DTT. The insets above the ν(O-O) difference 
spectra show the difference 16O2-
18O2 for ν(Fe-O) modes.  
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 Cholesterol bound oxy-CYP11A1: The 415.4 nm line from a Krypton ion laser, 
which in in resonance with the Soret transition of the CH-bound CYP11A1, was used to 
measure this complex. It is noted that, owing to relatively low S/N attainable for these 
frozen oxy- CYP samples, definitive identification of the key internal modes of the Fe-O-
O fragments are only accessible via generation of the 16O2/
18O2 difference traces, which 
are shown in Figure 3.3.11. The ν(Fe-O) are seen in low frequency region shown in traces 
(A) and (B) (insets) for oxy-CYP11A1 with and without Adx. The ν(O-O) were seen in 
high frequency region, shown in traces (A) and (B) for samples with and without Adx, 
respectively.    
In the low frequency spectra, the ν(Fe-16O) is assigned at 546 cm-1 and the ν(Fe-
18O) at 518 cm-1 for the cholesterol-bound form, a shift of 28 cm-1 (calculated 25 cm-1) As 
was outlined above in the first paragraphs of this section, this set of values for ν(Fe-O) 
and ν(O-O) is quite similar to that obtained for camphor-bound CYP101 and for 
oxyCYP17 and oxyCYP19 with those substrates that are known to converted via 
Compound I processing, the conclusion emerging form this being that conversion of CH 
to 22-OHCH also proceeds through a Compound I intermediate. This finding has long 
been generally been accepted, with recent EPR results providing strongly supporting data 
for the involvement of Compound I in this first step.51   Significantly, the sample 
prepared including the Adx exhibits a ν(Fe-16O) at 543 cm-1 and a corresponding ν(Fe-
18O) at 515 cm-1, this ~3 cm-1 down shift upon addition of Adx reflecting a slight 
weakening of the Fe-O bond when Adx is present. On the other hand, the ν(16O-16O) (at 
1136 cm-1) and ν(18O-18O) (at 1072 cm-1) modes shift up to 1139 cm-1 and 1075 cm-1 
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upon addition of Adx, the combined results suggestion that the interaction with Adx 
might slightly lower the tendency for the O-O bond cleavage process.   
22R-OHCH-bound oxyCYP11A1: Figure 3.3.11 shows the difference spectra for 
this species, both in the absence and presence of Adx. The high frequency region (right 
panel, traces C and D) shows the same pattern as was observed for the cholesterol-bound 
sample, exhibiting the ν(16O-16O) at 1135 cm-1, with the ν(18O-18O) being observed at 
1068 cm-1. Also like the CH-bound sample, upon Adx binding, the ν(16O-16O) shifts up to 
1137 cm-1, with the corresponding  ν(18O-18O) appearing at 1070 cm-1, yielding only a 
slighter larger isotopic shift.  Obviously, a key issue of interest is determining the status 
of the Fe-O bond for the enzyme bound with this 22R-OHCH substrate. Unfortunately, 
though numerous attempts to observe the telltale ν(Fe-O) mode were made, employing 
multiple excitation lines, including the 441.6 nm line from a He:Cd laser, no evidence 
was obtained for its enhancement. These efforts are summarized in the Supporting 
Information, along with a discussion of structural and electronic factors that can affect the 
degree of resonance enhancement of the internal modes of these Fe-O-O fragments. In 
the absence of observable ν(Fe-O) modes, it is not possible to draw conclusions about the 
status of the Fe-O-O fragment with regards to its disposition towards O-O bond cleavage 
vs the hydroxylation pathways, but the well-documented generation of the 20R,22R-
DiOHCH product is entirely consistent with the proposal that a Compound I intermediate 
is involved.  
20R, 22R-DiOHCH bound oxy-CYP11A1: Figure 3.3.11 also shows the difference 
spectra obtained for the oxy complexes of the 20R, 22R-DiOHCH-bound CYP11A1 
complex with Adx and without Adx. The difference pattern for the spectral region 
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containing the ν(O-O) modes were measured by Soret excitation (415.4 nm), as was done 
for the previous substrates; however, using this line for this complex, no clear difference 
pattern for ν(Fe-O) could be observed in the low frequency region. The same efforts were 
employed as were used to try to enhance the ν(Fe-O) modes of the 22R-OHCH sample. 
Though no success was realized using available excitation lines from the krypton laser, 
the ν(Fe-O) mode was effectively enhanced by using the 441.6 nm excitation line from 
the He:Cd laser. The data acquired for the enzyme bound with the 3rd substrate, 20R,22R-
DiOHCH, the ν(Fe-16O) stretch at 542 cm-1 and the ν(16O-16O) at 1135 cm-1. Interestingly, 
the effect of Adx binding on this species is opposite to its effect on the enzyme bound 
with the first two substrates; i.e., Adx binding to the samples containing the first two 
substrates increases the strength of the O-O bond, simultaneously decreasing the strength 
of the Fe-O bond, while the effect of Adx binding on the sample containing 20R,22R-
DiOHCH is to increase the strength of the Fe-O bond and decrease the strength of the O-
O bond. As can be seen from the CYP11A1+CH oxy complex, the frequencies here for 
ν(Fe-O) and ν(O-O) are very similar with oxy CYP11A1+CH and P450cam complexes 
with hydrogen bonding at terminal oxygen. This leads to the conclusion that the bond 
cleavage step proceeds through Compound I intermediate. With addition of Adx, the 
ν(Fe-O) increases124,133,155 indicating the increase of back bonding between Fe-O and 
strength the Fe-O bond. The decrease ν(O-O) indicates the weakening the O-O bond. 
Both of these shifts are consistent with a slightly stronger hydrogen bond donation to the 
terminal oxygen, a change that would increase favorability of the O-O bond cleavage of 
the Fe-O-O fragment and formation of Compound I.  
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3.4 Summary 
The results presented here show that the three natural substrates of CYP11A1 
have quite different effects on the active site structure, including variations of spin state 
populations, reorientations of heme peripheral groups and, most importantly, substrate-
mediated distortions of the Fe-XY fragments of bound exogenous ligands, including CO 
and O2, as revealed by telltale shifts of the ν(X-Y), ν(Fe-X) and δ(Fe-X-Y) vibrational 
modes. On the other hand, most significantly, our results reveal that the vibrational 
modes patterns observed for the Fe-O-O fragments of the dioxygan adducts obtained with 
the first and third substrates are almost identical, being consistent with H-bonding 
interactions to the terminal oxygen, a structural feature that tends to promote O-O bond 
cleavage and reactions mediated by the Compound I intermediate, as outlined above. 
Moreover, the effect of adrenodoxin binding to all three forms of CYP11A1 (ferric, 
ferrous CO and oxy forms) was studied and shows that, although Adx has small effect on 
ferric and ferrous CO states, it has a relatively stronger impact on the Fe-O-O fragments 
of the oxy complexes. 
Our newly acquired data are partially consistent with what was published 
previously, but also clarified the confusion due to the apparent photo-dissociation during 
the measurement in case of 22R-OHCH with CYP11A1 complex in ferrous-CO form.103 
Our data clearly show that the enzyme bound with the non-H-bonding substrate, CH, 
yields only one set of vibrational modes for the CO adduct; i.e., ν(Fe-C) at 482 cm-1 and 
ν(C-O) at 1952 cm-1. On the other hand, for the two substrates possessing hydroxyl 
substituents that are well positioned to H-bond with the bound Fe-C-O fragment, two sets 
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of Fe-C-O vibrational modes are seen. Thus, for both enzyme/substrate complexes, a 
ν(Fe-C)/ν(C-O) pair is seen at 482/1954 cm-1, which is quite similar that that observed for 
the non-H-bonding CH substrate. On the other hand, the presence of one or two H-
bonding hydroxyl groups near the Fe-C-O fragment generates a new set of modes having 
the ν(Fe-C) mode at 515 cm-1 (or 510 cm-1) and the ν(C-O)  mode at 1934 cm-1. Our data 
also shows this is minimal effect of Adx in ferric and ferrous-CO forms. 
Finally, a careful and thorough study of the rR spectra of the dioxygen adducts of 
CYP11A1 with all three substrates, revealed vibrational spectral patterns for the sample 
bound with 20R,22R-DiOHCH that were quite similar to those obtained for the first 
substrate, the non-H-bonding CH. Though it can be argued that the effective H-donor for 
these two cases might be different (water for CH and substrate hydroxyl for the 
DiOHCH), the Fe-O-O fragments in both cases are apparently well positioned to generate 
Compound I oxidative centers.  
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Appendix I Preparation of meso/proto hybrids 
1. Isolation hemoglobin from blood 
One unit of out-dated human blood around 300 ml was obtained from blood 
center in Marquette University. The blood was kept in the foam box contained with ice 
bag when transferring from blood center to our lab. Pour around 150 ml of blood in 
250ml centrifuge tube and then mix with 0.9% NaCl solution which is prepared in 
deionized water and cooled down to 4 C. Centrifuge the mixture at 4 C, 8000 rpm for 
10 minutes. The supernatant was removed with the white coating on the top of the red 
cells through a pipette connected with aspirator. Waste flows to the flask contained with 
bleach. This procedure was repeated three times and the final suspensions were 
centrifuged at 4 C, 10,000 rpm, 10 minutes.  
Mix 3 volume of 4 C deionized water with the red cells. Use glass rod to mix the 
solution well and keep at 4 C for one hour and then centrifuge at 4 C, 12,000 rpm for 
1.5 hours. The cell debris sticks on the wall of the bottle. Decant solution into a flask with 
cautious to avoid transfer any cell debris. Saturate with CO for 30 minutes with stir bar 
added in the solution. Separate the pure CO-hemoglobin into different tubes for storage 
purpose. Store the CO-hemoglobin in -80 C freezer for long term storage and -20 C 
freezer for relatively short period storage. 
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2. Make apo-hemoglobin 
Run CO-hemoglobin through an AG 501-X8 (D) Resin 20-50 mesh column with 
4 C deionized water in order to remove the heavy cation metal impurities. Adjust the 
concentration to be less than 1 mM determined by UV-vis spectrum. Acidic acetone was 
prepared by mix 1 L of HPLC grade acetone with 3 ml of 2 M HCl. Cool this solution to 
-20 C in a dry ice bath with constant stirring. Around 30 ml of CO-hemoglobin was 
added to the acidic acetone solution. The solution turned into a rust color which is due to 
the removal of heme into the solution. Incubate this solution for around 10 minutes. 
Centrifuge the solution for 20 minutes at -20 C, 10,000 rpm. Remove the apo-
hemoglobin which sticks on the wall and bottom of centrifuge tube. Dissolve this acetone 
contained apo-hemoglobin in deionized water. Dialysis apo-hemoglobin for three hours 
in deionized water. Then change to fresh deionized water to dialysis for overnight. The 
next morning, change dialysis buffer with 20 mM phosphate buffer (PB) pH=7.0 for three 
hours. Dialysis will allow to move any residual acetone and denatured protein.  
 
3. Make meso-hemoglobin 
Check UV-vis spectrum for previously prepared apo-hemoglobin and determine 
its concentration.  Weigh 1.2 molar excess of meso-heme and dissolve in a minimal 
amount of 0.1 M KOH. Dilute that solution with deionized water to reduce its basicity. 
Apo-hemoglobin was placed in a round flask with gentle stir on the ice bath. Dropwisely 
add the meso-heme solution into the flask. Keep the pH=6.0 by using 0.1 M KCl and 0.1 
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M KOH. When the addition was complete, allow the solution to stir for 5 minutes and 
then the mixture was saturated with Ar for 30 minutes to create an inert atmosphere. The 
mixture was kept at 4 C for three days to allow heme flipping in the active site which is 
the stable form of meso-heme.  
After three days, saturate under CO for 30 minutes. Excess amount of sodium 
dithionite Na2S2O4 was added to the solution. The color of the solution changed from 
brown to brilliant red. That is because the Fe3+ was reduced to Fe2+ by Na2S2O4. Let the 
solution stay under CO for another 5 minutes. Then run the sample through a G25 with 
20 mM PB pH=7.4 to remove excess Na2S2O4. This is the pure meso-hemoglobin. 
 
4. Make alpha and beta subunits 
Dialysis CO-hemoglobin in 20 mM PB pH=7.4 for overnight and then dilute to 
approximately 1 mM if the concentration is higher than 1 mM. The concentration was 
determined by UV-vis spectrum. Meso-hemoglobin is already in 20 mM PB pH=7.4. 
Calculate the amount of 4-hydroxymercuribenzoic acid sodium salt needed for separation 
of alpha and beta chain. For each gram of CO-hemoglobin or meso-hemoglobin with 
molecular weight 64 KDa is needed 100 mg of PMB. The PMB is used to break the thiol 
group thus reducing the affinity of subunits from one another. Put CO-hemoglobin or 
meso hemoglobin in a beaker with stir bar inside on the ice bath and stir. Add NaCl to 
make the NaCl concentration 0.25 M and mix well. Adjust the pH to 6.0 with 1 M 
KH2PO4. 
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Dropwise add minimum amount of 0.1 M KOH to dissolve PMB. A clear/yellow 
solution will appear when PMB dissolves. Dropwise add 0.1 M acetic acid and mix well 
until a slight turbidity persisted. Add this PMB solution into CO-hemoglobin or meso-
hemoglobin solution. Adjust the pH=6.0 by using 0.1 M acetic acid and 0.1 M KOH. 
After addition, mix well and then wrapped with aluminum foil. Keep the mixture at for 4 
C for overnight. 
The next day, centrifuge the PMB-hemoglobin solution for 10 minutes at 4 C 
6,000 rpm to remove excess PMB. Load the sample to P-6 Biogel column with 50 mM 
Tris buffer pH=8.4 (at room temperature pH=7.8). The entire sample was applied to a 
DE53 column equilibrated with 50 mM Tris buffer pH=8.4. The alpha-PMB subunit was 
eluted with the buffer and collected. The buffer was changed to 30 mM PB pH=7.4 to 
elute any unreacted hemoglobin. The buffer was changed to 100 mM PB pH=7.4 to elute 
beta-PMB subunit. Concentrate each PMB contained subunit. 
Run alpha-PMB subunits through a P-6 Biogel column with 100 mM PB buffer 
pH=7.4 contained 25 mM 2-Mercaptoethanpol (BME). PMB will be not bind with alpha 
subunit after treating with BME. After collection of BME treated alpha-PMB subunit, 
incubate for around 45 minutes and then run through a P-6 Biogel column with 100 mM 
PB pH=7.4 to remove PMB and BME. The sample is pure alpha subunit. Pure beta 
subunit can be obtained by same process just with 50 mM BME instead of 25 mM. Alpha 
and beta subunits are concentrated and stored at -20 C freezer for making hybrids. 
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5. Make proto and meso hybrids 
The Meso/Proto hemoglobin hybrids were made by mixing a 1.2 molar excess of 
beta subunits to alpha subunits. Slowly stir the mixture for 30 minutes to allow the hybrid 
mix adequately and then incubate the mixture at 4 C for overnight.  
The next day, run the sample through a P-6 Biogel column with 20 mM PB 
pH=6.4. Then the entire sample was applied on a CM52 column equilibrated by 20 mM 
PB pH=6.4. Excess beta subunit will pass through the column with buffer. Elute the 
tetrameric hybrids by changing buffer to 30 mM PB pH=7.0. Residual alpha subunit can 
be eluted by 50 mM PB pH=7.0. 
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Appendix II Preparation of Co/Fe hybrids 
1. Make Co/Fe hybrids 
Isolation of hemoglobin, preparation of apo-hemoglobin and separation of proto-
Fe subunits are described in previous section. The rest of the steps for preparation of oxy-
Co(II) hemoglobin will be addressed below. 
2. Preparation of oxy-Co(II) hemoglobin 
Prepare a degassed G-25 column which is washed by large amount of degassed 10 
mM PB pH=6.0 buffer. The column is placed in the glove bag at 4 C. The bag is also 
degassed by vacuuming the air out and filling the Ar in. That process will be repeated 
three times to insure no oxygen in the glove bag.  
An anaerobic equipment was set up to proceed reduce Co(III) in Co(III) 
protoporphyrin IX chloride (PPIX) complex to Co(II) and then reconstitute into apo-
hemoglobin. The set up was made by connecting two round bottom flask with stir bar 
inside and two air-tight vial with Ar. The round flasks and vials were sealed with rubber 
septa. They were connected with long needles to let Ar flow or transfer reactants from 
one to another. Apo-hemoglobin was placed in the round bottom flask which was in the 
ice bath with slowly continuous stirring. Weight 1.2 molar excess of Co(III) PPIX and 
place in another round bottom. Use minimum amount of pyridine to dissolve Co(III) 
PPIX and then add additional 10 mM PB pH=7.0 to reach a volume which is 1/10 the 
144 
 
 
 
volume of the apo-hemoglobin. This flask was also place on ice bath with slowly 
continuous stirring. Place 1 ml of 10 mM PB pH=7.0 in one vial and about 12 molar 
excess of Na2S2O4 in another vial. Seal the flasks and vials and connect them with 
needles attached with Ar gas. Degas the whole thing for 40 minutes. 
After 40 minutes degassing, immerse the needle in the vial which contains 1 ml of 
buffer. This will allow the buffer to transfer to another vial which contains 12 molar 
excess of Na2S2O4. Shake the vial so the Na2S2O4 will dissolve in the buffer. The same 
process is repeated to transfer the Na2S2O4 solution to Co(III) PPIX solution. Because 
Co(III) complex is inert due to its electron configuration, its t2g orbital is filled by 
electron. Fully reducing Co(III) to Co(II) will be insured by taking UV-vis spectrum. 12 
molar excess is usually enough to reduce Co(III) to Co(II). If there is some Co(III) 
residual detected by UV-vis, then more Na2S2O4 will be added following the above 
procedure. Degas some 1 M KH2PO4 and then store in a degassed syringe. Penetrate the 
syringe in the rubber septa on the round flask which contains apo-hemoglobin. 
Completely reduced Co(II) PPIX complex was transferred to apo-hemoglobin by 
immerse the needle in the Co(II) PPIX solution which was confirmed by UV-vis at 
different stage to make sure all Co(III) has been reduced to Co(II) by Na2S2O4. This 
process will be done slowly and in the mean time, add the solution in the syringe to let 
the apo-hemoglobin in the neutral or weak acidic environment. This will decrease the 
precipitate. Leave the flask on the ice bath for 5 minutes to let the reaction complete. The 
color is dark-red after the reaction completed.  
Apply the entire sample on the degassed G-25 column. This will allow to remove 
excess amount of Na2S2O4. Deoxy Co(II) hemoglobin will be collected and some of the 
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deoxy Co(II) hemoglobin will become oxy form when expose in the air. The solution will 
be placed on ice bath and saturated with O2 for one hour. The sample is applied on CM52 
column which is previously equilibrated with 10 mM PB pH=6.0. Pure oxy Co(II)-
hemoglobin will be eluted with buffer 100 mM PB pH=7.0. The sample is dialysis 
overnight against 20 mM PB pH=7.4 in order to proceed PMB treatment for subunits 
separation. 
3. Make alpha and beta subunits 
The PMB treatment to oxy Co(II) hemoglobin is identical to the previous 
procedure described in section 2.1.4. After incubating the PMB contained oxy Co(II) 
hemoglobin for overnight, centrifuge the sample for 10 minutes, at 4 C 6,000 rpm to 
remove excess amount of PMB. Run the sample through P-6 Biogel column with 10 mM 
PB pH=8.0. Then apply the entire sample to DE53 column previous equilibrated with 10 
mM PB pH=8.0. Alpha subunits is eluted with buffer 10 mM PB pH=8.0. Elute unreacted 
oxy-Co(II)-Hb with 30 mM PB pH=8.0. Then beta subunits was eluted with 100 mM PB 
pH=8.0. Concentrated subunits to around 10 ml. Add each subunit to a round bottom 
flask sealed with rubber septum, stir on ice bath and degas with Ar for 30 minutes. Add 
catalase to make the solution at concentration 5 µM catalase and DDT156 to make the 
concentration 20 mM. The addition process needs to be done in anaerobic environment 
created by flowing Ar around the flask. After addition, the solution is saturated with Ar 
for 5 minutes without stirring and then placed under Ar for 15 minutes with stirring. 
Incubate for 90 minutes at 4 C. Alpha subunits were applied on P-6 Biogel column with 
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10 mM PB pH=6.6. And then apply the entire sample to CM52 column previous 
equilibrated with 10 mM PB pH=6.6. Excess catalase will be eluted with the buffer 10 
mM PB pH=6.6 and pure alpha subunits is eluted with 50 mM PB pH=7.4. Beta subunits 
are applied on P-6 Biogel column with 10 mM PB pH=8.0. And then apply the entire 
sample to DE53 column previous equilibrated with buffer 10 mM PB pH=8.0. Pure beta 
subunits are eluted with 50 mM PB pH=7.4.  
The procedure of making Fe/Co hybrids are the same as described in previous 
section. Each hybrid is applied under O2 with a photolysis lamp to remove CO ligated for 
30 minutes. Oxygenated Fe/Co hybrids are obtained. 
 
 
